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ABSTRACT
THE EFFECTS OF EXERCISE TRAINING ON INSULIN SUPPLY AND
DEMAND IN BREAST CANCER SURVIVORS
MAY 2017
RICHARD VISKOCHIL, B.S., UNIVERSITY OF MIAMI
M.S.Ed, UNIVERSITY OF MIAMI
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Barry Braun

Elevated insulin concentrations may influence cancer and cardiometabolic disease
onset and prognosis, and lower insulin levels after exercise may contribute to disease
prevention and overall health. The effect of exercise training on systemic and tissuespecific insulin supply and demand in breast cancer survivors and adults at risk for
cardiometabolic disease is unclear. The objective of this dissertation was to evaluate the
effects of exercise training on postmeal insulin concentrations in breast cancer survivors,
and identify mechanisms responsible for changes to insulin supply and demand following
exercise training in breast cancer survivors and adults at risk for cardiometabolic disease.
Study 1 investigated differences between systemic and tissue-specific responses
to exercise training and/or the anti-diabetes drug metformin in adults with prediabetes.
Fasting proinsulin concentrations were lower following combined exercise and
metformin (-24%), and insulin clearance was higher in the metformin and combined
exercise and metformin groups (+19% and +17%). There were no differences in the
exercise or placebo group, and taken together with previous work from our lab, suggests
that exercise regulates insulin supply and demand systemically, while pharmacological
adaptations may be tissue-specific.
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Study 2 evaluated the effects of physical activity on postmeal insulin
concentrations in breast cancer survivors. Fifteen women completed 12 weeks of exercise
training with pre- and post-intervention oral glucose tolerance testing. Insulin
concentrations 120 minutes following glucose ingestion decreased (68.8±34.5 vs.
56.2±31.9 uU/ml, p<0.05), along with leptin (-22.7%) and estrogen (-20.9%), biomarkers
of cancer risk. This postmeal insulin response may have been blunted by the use of
aromatase inhibitors.
Study 3 assessed the specific components of insulin supply and demand that may
contribute to the blunted or absent postmeal insulin response observed in study 2. There
was a significant increase in estimated skeletal muscle glucose uptake following exercise
training (5.7±1.8 vs. 7.2 ±1.8, mmo*pmol*kg/m2 p<0.05), however there were no
changes to systemic measures of insulin supply and demand. This, combined with
reductions in leptin and estrogen (study 2), suggests that exercise training was sufficient
to induce tissue-specific adaptations but was unable to alter systemic insulin supply and
demand in breast cancer survivors.
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CHAPTER I
INTRODUCTION
Statement of the problem
The American Society of Clinical Oncology expects newly diagnosed cases of
cancer to double by the year 2030 and, as a result, cancer will dethrone heart disease as
the number one cause of death in the United States (ASCO, 2013). One in eight
American women will be diagnosed with breast cancer in their lifetime, and the majority
of these diagnoses will occur during or after menopause (Britt, 2012). The high rate of
breast cancer incidence, improvements in screening/treatment, and an aging population
have resulted in a large (and growing) number of postmenopausal breast cancer survivors
living in the United States, with recent estimates approaching 3 million women (Toriola
& Colditz 2013). While the majority of breast cancer survivors have been declared
cancer free, breast cancer treatment often induces physiological and psychological
changes that increase the risk of both cancer recurrence and cardiometabolic disease,
such as type 2 diabetes.
Three specific aspects of breast cancer treatment may influence breast cancer
recurrence and/or the risk of cardiometabolic disease. First, many chemotherapy drugs
impair cardiac function (Kirkham et al. 2015), which reduces aerobic fitness and
increases the risk of cardiovascular disease (Jones et al. 2016). These effects are not
confined to the periods of chemotherapy delivery alone, since most breast cancer
survivors immediately start a multi-year plan of secondary pharmacotherapy (e.g.
aromatase inhibitors) that can have detrimental effects on cardiovascular and bone health
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(Zagar et al. 2016, Hadji et al. 2011). Additionally, women undergoing chemotherapy
and radiation are given glucocorticoids (e.g. Dexamethasone) as anti-emetics, which
often raise glucose concentrations into the range of diabetes during treatment (Lu et al.
2014, JuanJuan et al. 2015). Finally, cancer treatment often induces physical and
psychological fatigue (Berger et al. 2012, Stagl et al. 2014), which leads to lower levels
of physical activity and increased sedentary behavior both during and after treatment.
Given the large and growing number of breast cancer survivors in the United States,
developing a greater understanding the relationship between modifiable cancer and
cardiometabolic risk factors and using that knowledge to design precision interventions
that improve prognosis has clear public health implications.
Being physically active reduces the risk of cancer recurrence and improves the
prognosis of cancer survivors (Moore et al. 2016). Epidemiological evidence suggests
that women who are meeting the US physical activity guidelines (150 min/wk of
moderate to vigorous PA) are 20% less likely to develop breast cancer, and breast cancer
survivors meeting the physical activity guidelines are 40% less likely to have a cancer
recurrence or cancer related death (Ballard Barbash et al. 2012). The mechanisms behind
this risk reduction are multi-factorial (e.g. weight control, reduced inflammation),
however the results of several large cross-sectional studies and randomized controlled
trials suggest that insulin may play a role (Ahern et al. 2013, Goodwin et al. 2012, Irwin
et al. 2005). The amount of insulin released into the circulation (insulin supply) is based
largely on the amount of insulin required by the body to maintain blood glucose
concentrations within a relatively tight physiological range (insulin demand). Obesity and
sedentary behavior reduce the effectiveness of insulin to regulate blood glucose, and this
2	
  
	
  

insulin resistance (i.e. increased insulin demand) causes a compensatory increase in
insulin supply in order to match the higher demand and maintain glycemic control.
Without this compensatory hyperinsulinemia most individuals with insulin resistance
(approximately 30-40% of the population in the United States) would likely develop
frank type 2 diabetes.
Although hyperinsulinemia helps restrain blood glucose and prevent T2D, it may
be detrimental to cancer risk. In addition to regulating blood glucose levels, insulin
stimulates cell growth and proliferation in both normal and cancerous cells (Gallagher et
al. 2013). In a study by Irwin et al. women in the highest quartile of circulating insulin
have a 3x greater risk of cancer mortality compared to women in the lowest quartile
(Irwin et al. 2011). Several recent epidemiological studies have also suggested a role for
insulin in cancer prevention. While the causal mechanisms are unclear, women who
regularly engage in physical activity or those taking the anti-hyperglycemia drug
metformin have a reduced risk of developing cancer, which is potentially mediated by
reductions in circulating insulin concentrations following each treatment (Goodwin et al.
2015, Del Giudice et al. 1998). Despite epidemiological and cell/animal model evidence
supporting a role of insulin in carcinogenesis, results from exercise training studies in
breast cancer survivors have been largely equivocal (Fairey et al. 2003, Ligibel et al.
2008, Irwin et al. 2009, Campbell et al. 2012 and Guinan et al. 2013). This has lead some
researchers to conclude that elevated insulin concentrations may contribute to
carcinogenesis, however exercise-induced reductions in insulin are either absent or play a
negligible role in cancer prognosis and/or the risk of recurrence in breast cancer survivors
(Irwin et al. 2009).
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One limitation of the prior interventions designed to evaluate the
mediating/moderating effect of insulin on cancer risk and prognosis is the use of fasting
insulin concentrations as the sole representation of glycemic control. Maintaining
appropriate glucose concentrations involves complex regulation of insulin supply and
demand on both a systemic and tissue-specific level across different metabolic states (e.g.
fasting, postmeal), all of which have unique responses to physical activity. For example,
fasting insulin concentrations primarily reflect the volume of insulin required for the liver
to maintain appropriate glucose production and prevent low blood glucose. After a large
meal however, insulin supply increases dramatically as insulin demand shifts from
restraining liver glucose production to inducing skeletal muscle glucose uptake. While
lean, physically active individuals tend to have lower fasting and postmeal insulin
demand compared sedentary obese individuals, there can be a large degree of discordance
between fasting and postmeal muscle insulin demand both within and across different
populations (Faerch et al. 2008). It is therefore possible for two individuals with very
similar fasting insulin concentrations to have significantly different postmeal insulin
concentrations due to differences in postmeal insulin demand (i.e. skeletal muscle insulin
sensitivity). Since insulin is a mitogenic, dose-dependent contributor to cancer risk, the
relationship between insulin and cancer likely cannot be extrapolated from fasting insulin
concentrations alone, as postprandial insulin represents an equal, and in some cases
greater, contributor to daily insulin exposure.
Additionally, changes to insulin supply and demand following interventions are
not similar in magnitude across all tissues and in all metabolic states. For example,
exercise training appears to reduce skeletal muscle insulin demand (i.e. insulin resistance)
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to a much greater degree than liver insulin demand. Since skeletal muscle insulin
sensitivity plays a significant role in postmeal, but not fasting, glycemic control, the
magnitude of reductions in postmeal insulin are significantly greater than the reductions
in fasting insulin following exercise training (Jenkins & Hagberg 2011). This response is
in contrast to other interventions like metformin, which primarily reduces fasting insulin
concentrations (Goodwin et al. 2008). Given the unique tissue-, and metabolic statespecific changes to insulin demand and supply, it is possible that studies evaluating the
efficacy of physical activity interventions on cancer risk and prognosis may be
undervaluing the impact of exercise training by failing to account for changes in postmeal
insulin concentrations.
Objectives and significance
Despite the disproportional relationship between fasting and postmeal insulin
concentrations and the unique tissue- and metabolic state-specific effects of interventions
on insulin supply and demand, many studies in breast cancer survivors only measure
insulin in the fasted state, and thus may be underestimating the role of insulin in cancer
risk and prognosis. Fasting insulin concentrations are only one component of insulin
supply and demand, and one that is not particularly reflective of the overall impact of
interventions on glycemic control. This limitation is especially relevant for exercise
training, as reductions in skeletal muscle insulin resistance are primarily reflected through
changes to postmeal insulin concentrations. While several clinical trials investigating the
role of pharmacology- and/or exercise-induced changes in metabolism in cancer
survivors are underway (Patterson et al. 2013), the health recommendations derived from
these studies are predicated on the changes to fasting insulin concentrations observed
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following each treatment. Before physical activity, dietary and pharmacological
interventions can be optimally combined into a personalized intervention to prevent or
reverse chronic disease, a full understanding of independent and combined effects of
these interventions must be elucidated in the populations that would most benefit from
them. Without a greater understanding of the tissue- and metabolic state- specific effects
of exercise training on insulin supply and demand in cancer survivors, the optimal utility
of physical activity as means to improve cancer prognosis and reduce the risk of
recurrence remains unknown.
The overall goal of this dissertation was therefore to address the current
limitations in our understanding of the interactions between physical activity, insulin
supply and demand and cancer risk. Study one evaluated the effects of 12-weeks of
exercise training and/or metformin on systemic and tissue-specific measures of
fasting insulin supply and whole-body insulin demand. This study used a fasting blood
draw and the hyperinsulinemic-euglycemic clamp technique to better classify the
responses to exercise training and/or metformin in men and women at risk for developing
cardiometabolic disease. Study two investigated the relationship between physical
activity, insulin and cancer by measuring fasting and postmeal insulin
concentrations and their relationship with cancer biomarkers prior to and following
a personalized 12-week aerobic exercise training program in breast cancer
survivors. This involved the use of a five-sample oral glucose tolerance test prior to and
following the completion of the exercise training protocol, with a primary focus on the
aspects of physical activity and insulin supply and demand that modify cancer risk.
Finally, in study three we investigated the potential influence of exercise training on
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cardiometabolic health in breast cancer survivors in order to identify any potential
changes to insulin supply and demand through which exercise training may reduce
cancer-specific and all-cause mortality in breast cancer survivors. The information
derived from this series of studies will shed light on the relationship between insulin
supply and demand, exercise training and cardiometabolic disease risk, as well as their
impact on cancer recurrence in breast cancer survivors, and guide future studies
attempting to develop precise and personalized interventions to improve cancer
prognosis.
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CHAPTER II
REVIEW OF THE LITERATURE
Overview of cancer development and treatment
This project pertains to exercise training in women who have been previously
diagnosed with breast cancer, received treatment, and have been deemed in remission or
“cancer-free” by their oncologist. Cancer diagnosis and treatment can have profound
effects on physical and psychological health and well being, and it is therefore necessary
to provide background information regarding the development and treatment of cancer.
This brief overview is by no means extensive, however it is important to review breast
cancer development and treatment in order to understand why the effects of an exercise
training program may differ between postmenopausal breast cancer survivors and noncancer survivors of similar age, BMI and cardiometabolic health profile.
Cancer develops due to genetic or epigenetic mutations that confer a selective growth
advantage to specific cells by 1) stimulating the cellular signaling pathways that lead to
cell proliferation and/or 2) inhibiting the cellular signaling pathways that suppress tumor
growth (Hanahan & Weinberg 2009). In most cases it takes many small genetic mutations
(over the course of many years) to “add up” to a mutation large enough to overcome the
inherent cellular defense mechanisms and manifest as a distinct physiological cancer
phenotype (Vogelstein et al. 2013). Most solid tumor (e.g. breast) cancers can therefore
be viewed as a stepwise genetic disorder associated with aging. This long process of
genetic mutation can be exacerbated through many physiological mechanisms within
individual control. For example, an individual may, after many years, have enough
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random mutations within his or her lung tissue to develop lung cancer. The length of time
required to develop this “mutation load” may be extensive, and the likelihood of this
mutation load reaching the point of metastasis, impairing breathing to a degree that would
result in death, or outpacing other potentially fatal diseases (e.g. cardiovascular disease)
is quite low. If however, he or she chooses to introduce a potent mix of carcinogens into
his lungs via smoking, the likelihood of a mutation increases steeply and lung cancer is
much more likely to develop over the course of his or her lifetime.
The modification of cancer risk through environmental factors within an
individuals control represents an arm of cancer research that is equally important as the
work being done on a genomic level, and equally as challenging (Vogelstein et al. 2013).
The most appropriate primary outcome for studies investigating how environment and
lifestyle (e.g. physical activity levels) may modify cancer risk is the development of
cancer. Despite the increasing prevalence of cancer in America, the randomized
controlled trials needed to establish causality or efficacy of prevention require very large
sample sizes and many years of follow-up, which is quite burdensome on participants and
researchers alike. Compounding the difficulty associated with evaluating cancer risk is
the fact that cancer is not a singular disease originating from a singular location, but
rather a collection of many different diseases with vastly discordant development
trajectories (Baird & Caldas 2013). While the goal of cancer treatment is to halt the
unregulated cell growth, prevent metastatic spread and eliminate (or vastly prolong)
recurrence, the ways in which oncologists accomplish this task is highly dependent on the
individual characteristics of the cancer. In order to understand the relationship between
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PA and breast cancer recurrence it is necessary to delineate some of the differences and
similarities in breast cancer development and treatment.
Breast cancer development
Breast cancer is a carcinoma arising from a mutation in the epithelial cells of the
breast tissue, either in the lactiferous ducts or the lobular cells that supply milk to the
ducts. The specific cause of the mutation can be multifactorial, however the primary
manifestation of the mutation is disruption of one (or more) proliferative signaling
pathways, such as PI3K/Akt (Dillon et al. 2007) or Ras-MAPK (Dunn et al. 2005), AND
disruption of tumor suppressor pathways such as p53 or PTEN (Weng et al. 1999). The
combination of enhanced cellular proliferation and loss of tumor suppression leads to
unregulated cell growth, forming a solid and often palpable tumor within the breast
tissue. Once detected, the size and growth rate of the solid tumor are then used to stratify
the development into a specific stage (0-IV). Stage 0, or carcinoma in situ, is a noninvasive carcinoma that has not spread to surrounding tissue, stages I-III are breast
cancers localized to the breast tissue, axillary lymph nodes and chest area, and stage IV is
metastatic breast cancer that has spread to other organs of the body (Matsen & Neumayer
2013). These stages represent the progression of the disease, predict much of the
physiological manifestations of treatment, and highly influence prognosis.
Since cancer is typically driven by a single mutated cancer stem cell (or several
from within the same line of cells), receptors on the surface of the mutated cancer stem
cell will be expressed ubiquitously on almost all of the cancerous cells throughout the
tumor (Gupta et al. 2009). Tumors expressing the estrogen receptor (ER) and
progesterone receptor (PR) fall under a similar category of hormone receptor positive
10	
  
	
  

cancers, which can be used for treatment as well as prevention by binding to that receptor
and delivering drugs or preventing cell replication. The majority of breast cancers are
hormone receptor positive cancers (>85%, Britt 2012), and it is common for women
diagnosed with ER+ cancer to be given endocrine therapy, designed to inhibit estrogen
production or binding, for five to ten years after successful primary treatment (Goss et al.
2016). An additional receptor known as the HER2/neu receptor is not responsive to
estrogen-based therapy but does respond to other chemotherapy, notably herceptin. A
breast tumor that is negative for ER, PR or HER2 expression is referred to as triple
negative breast cancer, a much more worrisome diagnosis due to the lack of
chemotherapeutic treatment options and in many cases a much more aggressive mutation.
The specific differences in staging and receptor status are the primary components
of cancer diagnosis, and play the largest role in prognosis for successful treatment. More
advanced stage (e.g. IIIA) is typically associated with reduced levels of PA following
treatment (Mason et al. 2013), which may be due in part to greater fatigue induced by
more aggressive chemotherapy (Blaney et al. 2013) or more intensive surgical procedures
and lymphedema (Schmitz & Speck, 2010).
Breast cancer treatment
Treatment for breast cancer involves surgery and (when necessary) radiation
therapy to remove the cancer localized within the breast and axillary lymph nodes, as
well as the use of chemotherapy based on the specific expression of receptors on the
surface of the cancerous cells.
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Surgery represents the most common treatment for breast cancer, and can range
from orthoscopic surgery with minimal invasiveness to a full mastectomy (including the
removal of lymph notes and non-breast tissue) that could impact range of motion and
lymphatic function (Boquiren et al. 2016). Extensive removal of axillary lymph nodes
increases the risk for the development of lymphedema during physical activity, and may
contribute to the lower physical activity levels observed in breast cancer survivors
(Paskett et al. 2012). Radiation therapy involves targeted use of ionizing radiation to
disrupt replication of cancer cells. Fatigue, nausea and localized discomfort or burning
may accompany radiation therapy, and can contribute to the cancer-related fatigue and
increase in sedentary behavior observed in individuals undergoing cancer treatment
(Taunk et al. 2011), albeit to a lesser degree than surgery and chemotherapy.
Chemotherapy involves delivery of compounds and toxins designed to prevent
cell replication and thus disrupt tumor growth and viability. Unlike surgery and radiation,
chemotherapy is delivered systemically, and therefore has the largest impact on systemic
physiology, cardiometabolic disease and physical activity. Chemotherapy may impact
physical activity and exercise training both during and after treatment via cardiovascular
impairment, nausea-induced anti-emetic use and fatigue. The impact of these three
detrimental aspects of chemotherapy on physical activity, cardiometabolic health and
cancer recurrence will be discussed in greater detail later in this review.
Women who have been treated for estrogen receptor positive breast cancer will
often be prescribed drugs designed to disrupt estrogen binding for five to ten years after
conclusion of primary treatment in order to reduce the risk of cancer recurrence. These
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drugs, often referred to as secondary treatment, fall into two broad classes that have wideranging effects of metabolism and health.
For many years SERMs (e.g. Tamoxifen) were the primary means by which the
potentially mitogenic effects of estrogen were controlled in breast cancer survivors
(Chlebowski 2000). This class of drugs binds to the estrogen receptor and exhibits pro- or
anti-estrogenic activity, depending on the tissue (Huang et al. 2015). In breast tissue,
SERMs play and anti-estrogenic role, inhibiting the cellular activity of estrogen within
breast cells. There are several known side effects of SERM use, including clotting
disorders and elevated risk of other types of cancer, including endometrial cancer (Chen
et al. 2014). Most studies support a beneficial role of SERM use for the prevention of
cancer recurrence, and they are currently the most commonly prescribed secondary
cancer prevention drugs to premenopausal women (Chojecki et al. 2014), due to their
ability to block estrogen binding in certain tissues while allowing estrogen production to
continue in the ovaries.
Aromatase inhibitors block the conversion of testosterone and anabolic precursors
into estrogens, and, as a result, circulating concentrations of estrogen can be reduced to
levels virtually undetectable in circulation. Longitudinal and case-control studies suggest
that AI’s are more effective in reducing cancer risk than SERMS, with fewer high-risk
side effects (e.g. stroke), and they are currently used as the primary means of endocrine
therapy for postmenopausal women (Amir et al. 2011). Recently, several studies have
advocated for breast cancer survivors to remain on AIs for up to 10 years following
remission, with some oncologists recommending lifelong adherence for those that can
tolerate the drug and do not manifest many of the side effects (Goss et al. 2016). These
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side effects are primarily related to bone and joint health, including an increased risk of
osteopenia/osteoporosis (Becker et al. 2012), as well as increased risk of arthralgia and
joint pain (Niravath 2013). There is no evidence that AIs interfere with cardiovascular or
metabolic health (Younus et al. 2011), however the evidence has primarily focused on
their safety, and the long-term evaluation of their efficacy as well as their interaction with
other pharmacological agents or lifestyle interventions is still being evaluated (Foglietta
et al. 2016).
Summary of cancer development and treatment
Cancer is a multifaceted disease that has at its core genetic mutations that confer a
selective growth advantage by increasing cell proliferation and inhibiting or abrogating
tumor suppression. These mutations take many years to develop, and solid tumor cancers
are often viewed as a disease of aging exacerbated by lifestyle choices (e.g. smoking,
inactivity). Breast cancer is a specific type of carcinoma in which the mutation develops
in the mammary epithelial tissue. Breast cancer treatment varies based on progression
(stage 0-IV) and receptor status, (ER, PR, HER2 +/-; triple negative), and the techniques
used to treat breast cancer (surgery and radiation with or without chemotherapy) are
employed on a personalized basis with the overall goal of halting progression and
preventing recurrence. The physiological manifestations of this personalized treatment
include large inter-individual differences in the response to exercise interventions among
breast cancer survivors.
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Mediators and moderators of cancer development and prognosis
Overview of cardiometabolic health and cancer
While cancer is primarily a genetic disorder associated with aging, 30-50% of
cancer cases are directly caused, or exacerbated by, environmental factors and lifestyle
choices that may be within individual control (McKenzie et al. 2015). To evaluate the
impact of a lifestyle intervention designed to increase physical activity (e.g. exercise
training) on cancer recurrence, it is important to understand how physical activity levels
and obesity moderate and/or mediate cancer risk. Additionally, the third aim of this
project is to evaluate the impact of exercise training on cardiometabolic health in cancer
survivors, which requires some background on the overlap between cancer and
cardiometabolic disease.
Both incidence and prevalence of obesity and inactivity have risen exponentially
over the last 50 years in the United States and abroad (Yang & Colditz, 2015). When
combined with an aging population, these twin epidemics of obesity and sedentary
behavior have lead to a significant increase in the prevalence and incidence of both
cancer-specific and all-cause mortality, which is often the result of cardiometabolic
disease (Chang et al. 2013). Investigators who focus on systemic physiology and the
response to obesity, sedentary behavior, and lifestyle interventions have recently begun to
envelop factors that impact both cardiovascular and metabolic disease under the blanket
term “cardiometabolic health.” This phrase is beneficial due to the strong relationship
between diabetes and cardiovascular disease, the similarity between the general
pathology of each disease, and the shared beneficial response to lifestyle interventions
targeting obesity and inactivity. The use of cardiometabolic health and disease within this
15	
  
	
  

section and throughout the rest of the document can therefore be interpreted as
“cardiovascular and/or metabolic” health and disease, specifically as it pertains to
obesity, inactivity, and lifestyle interventions such as exercise training.
Postmenopausal women have a significantly higher risk of developing cancer
and/or cardiometabolic disease than premenopausal women (Britt 2012), and both obesity
and inactivity contribute to this increased risk (Su et al. 2013). Additionally,
postmenopausal women with cardiometabolic disease also have a higher risk of
developing cancer or having a cancer recurrence (Eulenberg et al. 2016) compared to
postmenopausal women without cardiometabolic disease. The primary aim of this section
of the literature review is twofold; 1) to establish the impact of inactivity and obesity on
cancer and cardiometaboic disease risk in postmenopausal women and 2) to identify
potential areas where a previous cancer diagnosis and treatment places postmenopausal
women at greater risk of cardiometabolic disease or cancer than age- and BMI- matched
women without a cancer diagnosis. It is important to note that cancer survivors remain
susceptible to cancer even if they have been aggressively treated for cancer in the past
and been declared cancer free. While a double mastectomy may virtually eliminate the
risk of a subsequent breast cancer diagnosis, the risk of developing other cancers remains
at least the same, and in many cases may be greater due to side effects of the breast
cancer treatment.
Inactivity
Many postmenopausal women do not meet the physical activity guidelines
(McTiernan et al. 1998), and this number is even greater in postmenopausal breast cancer
survivors (Bluthmann et al. 2015). Sabiston et al. found that breast cancer survivors
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spend an average of 78% of waking hours sedentary and just 2% of each day engaged in
moderate-to-vigorous physical activity (MVPA). Not only is this volume of sedentary
time consistent throughout the first year after treatment, the levels of MVPA decrease as
the year progresses (Sabiston et al. 2015). The specific mechanism behind the increased
sedentary time and reduced physical activity observed in breast cancer survivors is
unclear, however it appears to be closely related to fatigue severity (Bower et al. 2000).
Inactive breast cancer survivors are also more likely to report having poor quality of life
compared to inactive age- and BMI-matched non-cancer controls (Meeske et al. 2007),
which increases the likelihood of developing cardiometabolic disease (Rozenberg et al.
2007).
Paradoxically, women receiving chemotherapy in addition to surgery have
significantly lower objectively measured sedentary time and higher MVPA than women
who received surgery alone (Phillips et al. 2016), despite the greater fatigue induced by
chemotherapy. While the specific nature of the association between objectively
measured physical activity and sedentary time and cancer recurrence is still unclear,
randomized controlled trials and case-control studies have clearly demonstrated both
increased sedentary time and decreased physical activity in cancer survivors contributes
to elevated risk of cardiometabolic disease compared to age- and BMI- matched
postmenopausal women without a cancer diagnosis (Colditz et al. 2016, Jones et al. 2016,
Foraker et al. 2016). Specific interventions designed to increase physical activity through
exercise training, and their effects on cardiometabolic health, will be discussed later in
this review.
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Obesity
Obesity is a significant contributor to both cancer and cardiometabolic disease
development (McTiernan 2005, Ndumele et al. 2016), and increases the risk of both all
cause and cancer specific mortality after cancer diagnosis (Chang et al. 2013, McTiernan
et al. 2010). Recently, the World Cancer Research Fund estimated that 17% of breast
cancer diagnoses were a direct result of obesity (WCRF Food, nutrition, physical activity
and the prevention of cancer global report, 2014), and Howell et al. estimated that weight
loss, coupled with increased physical activity and a reduction in alcohol consumption,
would reduce the risk of cancer development by 30% (Howell et al. 2014).
While the increased risk of cardiometabolic disease due to obesity is fairly consistent
across the lifespan, this is not the case for the relationship between obesity and breast
cancer risk. Overweight and obesity may have a protective effect on breast cancer risk in
premenopausal women, but significantly increase the rate of breast cancer development
in postmenopausal women (Hsieh et al. 1990, Chlebowski et al. 2015). The direct
mechanisms for the discordant relationship between obesity and cancer risk based on
menopause status are unclear, but it appears to impact and overlap with several systemic
aspects of obesity. For example, one of the hallmarks of obesity-induced increases in
cardiometabolic disease risk is the development of insulin resistance and elevated
circulating insulin levels. The mechanisms behind insulin resistance and
hyperinsulinemia will be discussed (in great length) later in this review, however it is
important to note that while there is a significant association between insulin and both
cancer development and recurrence in postmenopausal women (Goodwin et al. 2008), no
such relationship exists between cancer development, insulin resistance and/or
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hyperinsulinemia in premenopausal women (Eliassen et al. 2007). The difficulty of
studying the relationship between cancer, obesity, and the bioenergetics behind obesity
has been well documented, and several large clinical trials are currently underway with
the express purpose of clarifying the complex mechanisms behind the obesity-induced
increase in cancer risk (Patterson et al. 2010).
Chemotherapy-induced cardiometabolic disease
The primary goal of chemotherapy is to deliver chemicals that will significantly
impair or halt the ability of the cancerous cells to grow and/or replicate, however the
systemic delivery of chemotherapy can induce profound changes to cardiometabolic
health. These changes not only affect women during the months of chemotherapy, but
also may impact health outcomes for years.
Several recent studies have identified an unusually high percentage of women
who have blood glucose concentrations that move from the normal range into the range
of T2D during chemotherapy (JuanJuan et al. 2015). Interestingly, the majority of these
cases of chemotherapy-induced transient diabetes are only identified through postprandial
glucose and/or hemoglobin A1c values (Lu et al. 2014), suggesting that the common
measure of glycemic control during cancer treatment (fasting blood glucose) may be
vastly underestimating the impact of chemotherapy on glucose homeostasis. The most
likely culprit for this transient diabetes is a combination of reduced physical activity and
glucocorticoids regularly given during treatment as anti-emetics. Glucocorticoids
increase glucose concentrations through a combination of increased glucose production
and decreased insulin sensitivity, and the elevated glucose concentrations mostly return to
normal following cessation of treatment (Wu et al. 2015). While there have been no
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longitudinal studies investigating the role of glucocorticoid use or elevated blood glucose
during cancer treatment as risk factors for the subsequent development of frank T2D,
evidence from other situations that induce transient diabetes and/or insulin resistance
(e.g. gestational diabetes, polycystic ovary syndrome) suggests this would be highly
likely (Appelman et al. 2015).
Cardiovascular fitness and maximal aerobic capacity (VO2max) represent key
predictors of cardiometabolic disease risk, and emerging evidence suggests that many
chemotherapeutic agents have a detrimental effect on aerobic fitness. A recent metaanalysis by Peel et al. that evaluated 27 different studies in which VO2max was
determined prior to and after chemotherapy found a significant reduction in aerobic
fitness due to the chemotherapy, and this could only be partially explained by reduced
levels of physical activity (Peel et al. 2014). Jones et al. recently quantified the decline in
VO2max following cancer treatment in terms of the age-related decline in
cardiorespiratory fitness, and found that a group of women who enter chemotherapy with
the average aerobic capacity within the normal range for 60 year old women have aerobic
capacity more reflective of 80 year old women following an average of 6 months of
treatment (Jones et al. 2016). As discussed in the previous paragraph, this precipitous
decline in aerobic fitness following cancer treatment is not met with a vigorous exerciseinduced rebound following completion of treatment, but rather with a decline in MVPA
in the year following treatment completion.
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Summary of moderators of cancer progression
While the root of cancer is a genetic mutation that confers a selective growth
advantage in certain cells, inactivity and obesity both can significantly contribute to
cancer development, recurrence and cancer-specific mortality. Additionally, there
appears to be a relationship between cardiometabolic disease and cancer recurrence, both
as a direct relationship (e.g. women with diabetes are more likely to develop cancer) as
well as the shared common root of obesity and inactivity. The systemic impact of
inactivity and obesity, as well as the difficulty of measuring the “crosstalk” between
many of the tissues and organs that link obesity and inactivity with cardiometabolic
health (e.g. adipose tissue, skeletal muscle), have made it difficult to determine the
precise mechanistic relationship between cancer and cardiometabolic health. This
difficulty is compounded by the large sample size necessary for cancer research; while
cancer rates are rising, evaluating cancer risk with the primary outcome of cancer
development (or recurrence) still requires large sample sizes and many years of followup. For smaller studies designed to test the efficacy of interventions designed to target
inactivity and/or obesity in order to determine the impact on cancer and cardiometabolic
disease risk, surrogate measures, such as biomarkers, are required
Biomarkers of cancer development and prognosis
Over the last 20 years several cross-sectional and longitudinal epidemiological
studies that are large enough to use cancer diagnosis as a primary outcome, such as the
Women’s Health Initiative (Thomson et al. 2014), the Nurses Health Study (Eliassen et
al. 2010) and NHANES (Lynch et al. 2011), have contributed much to the understanding
of cancer risk and prognosis, especially as they pertain to lifestyle factors (e.g. obesity,
21	
  
	
  

inactivity). These epidemiological studies are vital links in the research chain, and have
served as the primary “jumping off point” for many subsequent randomized controlled
trials, case-control studies and interventions. A major contribution of these longitudinal
epidemiological studies was the identification of biomarkers associated with cancer. The
strength of these biomarkers with respect to cancer-specific or all-cause mortality is in
fairly constant flux, and the associations between these biomarkers and cancer risk range
from moderate to weak. Despite this limitation, biomarkers of breast cancer risk and
recurrence represent the most viable metric by which intensive short-term (e.g. 3-12
month) lifestyle interventions can study cancer risk in human beings. Many of the
biomarkers are not localized to the cancerous tissue, and have wide-ranging effects that
are not directly related to tumorigenesis or cellular growth. It is therefore not enough to
simply identify the circulating quantities of the biomarker and block (or reduce) it’s
activity, as that may have wide-ranging detrimental (and potentially life-endangering)
effects.
Given the difficulty of using systemic hormones and metabolites as cancer
biomarkers, studies making use of them must also include 1) the mechanisms of action of
a hormone/metabolite within the specific cancerous tissue 2) the effects of the biomarker
on non-cancerous tissue and 3) the potential interaction of two or more biomarkers on
cancerous and non-cancerous tissue. This three-pronged approach may appear arduous,
especially when one considers that in many cases these biomarkers do not CAUSE cancer
(i.e. are carcinogens), but instead increase the RISK of cancer development and/or
ENHANCE tumor growth (i.e. are mitogens). However, until biomarkers directly
associated with tumorigenesis and/or genetic profiling can be identified, understanding
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the nature and interaction of biomarkers associated with risk of recurrence is critical for
interpreting projects in which a relationship between metabolism and cancer must be
established.
Insulin
Insulin is a peptide hormone secreted from the pancreas that has wide-ranging
metabolic effects on many different tissues throughout the body. Insulin is a primary
anabolic hormone, and the majority of the effects of insulin on cellular tissue are to
induce nutrient uptake, storage and cell growth. Several other studies have identified a
relationship between hyperinsulinemia, poor breast cancer treatment prognosis (Ahern et
al. 2013), and increased risk of breast cancer recurrence (Irwin et al. 2011), However,
these findings are by no means uniform, and other researchers have either observed very
weak or absent relationships (Minatoya et al. 2013, Sieri et al. 2012), or have been unable
to disentangle hyperinsulinemia from the myriad inter-related concurrent symptoms of
obesity and/or metabolic syndrome that have all been identified as potential mediators or
moderators of breast cancer risk (Capasso et al. 2013). In order to clarify the potential
role of hyperinsulinemia as a causal mechanism of increased risk of breast cancer
recurrence, an investigation into the cellular relationship between insulin and cancer
development is warranted.
The intricate relationship between insulin and insulin-like growth factors (IGFs) is
often cited as the primary means by which circulating insulin can induce cellular
proliferation, but insulin alone can provide enough impetus to cause aberrant cellular
growth (Rostoker et al. 2013). The signaling pathways induced by insulin are farreaching and varied, however the ones most associated with cellular proliferation are the
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PI3K/Akt and MAPK pathways (Weinstein et al. 2009). Briefly, insulin binds to a
tyrosine kinase receptor on the surface of the cell, which activates insulin receptor
substrate 1 (IRS-1) and induces phosphorylation cascades through the activation of PI3K
and MAPK. The phosphorylation of PI3K induces the phosphorylation of Akt, mTOR
and p70S6k, while phosphorylation of MAPK induces the phosphorylation of the
Ras/ERK/MEK pathway, both of which induce cell proliferation (Weinberg 2008).
Mutations in these pathways are often present in all types of cancer, and can represent the
acceleration of proliferation that is akin to “stepping on the gas pedal” which, when
combined with loss of tumor suppressor genes, leads to unchecked cell growth and
tumorigenesis.
Both insulin and the genetic mutations that induce cancer cell proliferation
activate similar phosphorylation cascades, and indeed several studies have demonstrated
a strong relationship between exposure to insulin and cell proliferation in cancer cell
models (Milazzo et al. 1997, Rostoker et al. 2013). Additionally, blocking the PI3K
signal cascade appears to reduce the size of mammary tumors in a hyperinsulinemic
mouse breast cancer model (Gallagher et al. 2012, Novosyadlyy et al. 2010), albeit with
the unfortunate side effect of severe hyperglycemia. The specific mechanism behind any
potential mitogenic action of insulin is poorly understood, likely due to the intricacy of
the signaling cascade. In addition to the role insulin may play in tumorigenesis through
overactivation of these critical phosphorylase cascades, hyperinsulinemia may also
increase the activity of insulin receptors themselves, another potential mechanism of
cancer cell proliferation (Gallagher et al. 2013). Finally, it has recently been
demonstrated that insulin suppresses the metabolic intermediate PTEN, a potent tumor
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suppressor that inhibits PI3K/Akt pathway expression (Liu et al. 2013). This suggests that
hyperinsulinemia may be helping cells “step on the gas” through enhanced proliferation
and “take the foot off of the brake” through inhibition of tumor suppression at the same
time.
There are several limitations in generalizing the results of these cell culture and
mouse model studies to systemic human cancer development. First, these studies often
are demonstrating proof of concept through activation of a specific signal cascade
intermediate, and therefore insulin exposure is often higher and of greater duration than
what would normally be observed in even the most hyperinsulinemic individuals. Along
similar lines, even those studies that reduce the insulin exposure to physiological levels
use static exposure, which does not represent the cyclical insulin release in humans.
While the precise mechanisms are unclear there is consensus that insulin
represents a mitogenic, rather than carcinogenic, compound on a cellular level (Call et al.
2010). If we equate the spread of cancer to an uncontrolled wildfire, insulin likely does
not provide the spark that triggers the mutation leading to cancer. But hyperinsulinemia
may add fuel to that spark, allowing a fire to grow where it would otherwise not via
overexpression of PI3K/MAPK pathways, enhanced insulin receptor activity, and
inhibition of tumor suppressor activity. Additionally, it appears that the mitogenic
response to hyperinsulinemia is highly variable (Beelen et al. 2014, Baxi et al. 2012). To
extend the wildfire analogy to its terminus, in some cases the hyperinsulinemia plays a
minimal role, such as a few leaves on a blazing bonfire, however in others
hyperinsulinemia behaves more like dumping lighter fluid on a candle. It is unclear what
specifically causes insulin to show such a high degree of variability, and further research
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in this area is required before any definitive conclusions may be made regarding the
direct cellular influence of insulin on cancer development. In addition to this direct role
of insulin as a biomarker of cancer development, the myriad roles of insulin throughout
the body create several other mechanisms by which hyperinsulinemia can mediate or
modify cancer risk. The two areas that appear to contribute the most in breast cancer are
through the homology and cross-reactivity between insulin and insulin-like growth
factors (IGFs) and through the effects of insulin on the activity of the sex hormones,
specifically estrogen.
Insulin-like growth factors and binding proteins
IGFs represent a distinct class of molecules with high sequence homology to
insulin (hence the name), but with markedly different physiological roles and regulation.
Structurally these molecules exist in a complex composed of one of the two specific
factors (IGF-1 and IGF-2) and are typically associated with one of six binding proteins
(IGFBP1-6) (Rosen et al. 1991). Unbound IGFs bind to two different types of receptors
(IGFR1 and IGFR2) that induce cellular proliferation and growth through interaction
with growth hormone (Vottero et al. 2013). IGF-1 is the primary circulating IGF in
adults, and is found in almost every tissue in the body. The ubiquitous nature of IGF-1 as
one of the, if not the, primary regulators of cell growth (including exercise-induced
skeletal muscle hypertrophy) results in widely discordant and opaque views on the role of
IGF-1 in health, aging and disease (Berryman et al. 2008). Liver production and secretion
is primarily responsible for circulating (as opposed to tissue specific) IGF-1 and the
proportion of IGF-1 bound to associated IGFBPs dictates its physiological activity.
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IGFBP1 and IGFBP3 appear to bind to IGF-1, hindering its ability to bind to the IGF1R
and induce cell proliferation and growth (Yeap et al. 2011).
Results have been mixed (Shernhammer et al. 2006), but current epidemiological
evidence suggests that elevated IGF-1 levels positively correlate with ER+ breast cancer
development in women over 50 (Key et al. 2010, Kaaks et al. 2013). Additionally, the
ratio of IGF-1/IGFBP3 has been widely used as a metric to assess the bioactivity of the
IGF system in the development of all forms of breast cancer, with positive associations
between IGF-1/IGFBP3 ratio and mortality in breast cancer survivors (Duggan et al.
2013). The reasons behind a specific type (ER+) and age range being more susceptible to
breast cancer are unknown, however it is possible that there is some interaction between
IGF-1 and estrogen, which will be discussed later in this section. Elevated IGF-1 and
Reduced IGFBP also appear to be related to hyperinsulinemia and may combine
synergistically to increase the risk of cancer development (Malin et al. 2004). The precise
nature of the relationship between insulin binding to the insulin receptors and IGF-1
secretion from the liver is unclear, however recent studies suggest that it may be a result
of hyperinsulinemia interfering with the actions of IGFBP3 and its binding affinity with
IGF-1, thus increasing the bioavailable supply of circulating IGF-1 (Yamada et al. 2010,
Kaaks et al. 2001).
The close homology between insulin and IGF-1, as well as their cellular receptors,
may serve as an additional means by which hyperinsulinemia increases the risk for breast
cancer development and/or recurrence. For many years it was a mystery how vast
differences between insulin signaling (nutrient uptake, metabolism) and IGF-1 signaling
(cell proliferation and growth) could exist despite the close homology between insulin
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receptors (IRs) and IGF receptors (IGFRs) and the virtually identical signal transduction
cascades. Work in the late 1990s identified a specific set of pre-receptor ligand binding
interactions between IGF and IGFBPs that effectively “set up” the system for the
appropriate phosphorylation and cellular result (Mynarcik et al. 1997). However, just as
this mystery was being solved IR/IGFR hybrids were identified (Federici et al. 1998), and
these receptors were responsive to both insulin and IGF-1 (Belfiore et al. 2009). These
receptors typically exist in extremely small quantities, however they become hyperactive
and overexpressed in many cancer cells, including breast cancer cells (Pandini et al.
1999). Results from several studies using a breast cancer mouse model generated by
LeRoith and colleagues suggests that the overexpression of IR/IGFR hybrids in the
presence of systemic hyperinsulinemia results in enhanced risk of breast cancer
development and greater tumor load (Novosyadlyy et al. 2010).
The specific role that these IR/IGFR hybrids may play after diagnosis and
treatment of breast cancer in humans is unclear, however it provides a secondary
mechanism by which high insulin and/or high IGF-1 may activate the PI3K/Akt and
MAPK pathways and increase the risk for recurrence of breast cancer after treatment.
Sex hormones
There has been extensive research into the role of sex hormones, specifically
estrogens (e.g. 17-b estradiol) and their receptors, on the development of breast cancer.
Thoroughly delineating the relationship between estrogen and breast cancer would
encompass an entire literature review, however there are several key concepts that have
bearing on this project, and therefore warrant discussion. For simplicity, all subsequent
information presented in this section will be with respect to postmenopausal women.
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There are several key manifestations of this distinction. First, while premenopausal
women produce estrogen in the ovary (which may enhance cardiometabolic protection),
postmenopausal women produce estrogen primarily in adipose tissue. This estrogen
production is under the primary regulation of a complex of enzymes known as aromatase,
which converts androgens into estrogen within the adipocytes (Bulun et al. 2012). In
addition to the activity in the adipose tissue, aromatase can become highly active in the
adipocytes of the breast, greatly increasing the local concentrations of estrogen (Sebastian
et al. 2002). Since this aromatase activity is localized in adipose tissue and adipocytes,
there is a high degree of correlation between fat tissue and circulating estrogen
concentrations in postmenopausal women (Perry et al. 1998). Additionally, a strong
correlation exists between circulating estrogens and breast cancer risk in postmenopausal
women (Zhang et al. 2013, Licznerska et al. 2008), suggesting that adipocyte-derived
estrogen plays a significant role in breast cancer development and recurrence.
This correlation also appears to hold for androgen levels (Folkerd, 2013), which
represent the precursors for estrogen. Approximately 75-85% of breast cancers are ER+
or PR+ (Glass et al. 2007), and often exhibit overexpression of estrogen receptors on the
surface of cancer cells. The elevated circulating estrogen concentrations derived from
adipose tissue may initiate a signaling cascade by activating these receptors, leading to
cell proliferation and growth which is enhanced through the localized estrogen
production in the adipocytes of breast tissue. In support of this correlation between
obesity, estrogen and cancer risk, weight loss appears to significantly reduce circulating
estrogen concentrations in postmenopausal women as well as significantly reduce the risk
of cancer development. This risk reduction occurs regardless of whether that weight loss
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is achieved via diet (Wasserman et al. 2004), physical activity (Friedenreich et al. 2011)
or their combination (Carpenter et al. 2012), provided the primary means of this weight
loss is through reductions in adiposity.
Insulin appears to play an active role in estrogen production within the adipocytes
by increasing a specific type of aromatase activity that converts androstenedione to
estrone (McTernan et al. 2000), which can then either be released into the general
circulation as estrone or undergo an additional conversion to estradiol prior to subsequent
release. The magnitude of this increased production of estrone and estradiol due to
hyperinsulinemia is not clear, however it appears to occur in all adipose tissue and breast
cancer cell models (Lisztwan et al. 2008), indicating that the specific magnitude of effect
would be increased with higher degrees of insulin and/or greater volume of adipose
tissue. In addition to regulating production of estrogen, hyperinsulinemia can also modify
bioactive adipose-derived estrogen concentrations by reducing the activity of sex
hormone binding globulin (SHBG), which attaches to estrogens and androgens and
deactivates them (Tymchuk et al. 2000). SHBG is produced by the liver in response to
circulating estrogen and androgen concentrations, however it has a high degree of
negative regulation through the activity of several primary hormones and growth factors,
most significantly insulin and IGF-1 (Kaaks et al. 2005). This downregulation of SHBG
occurs in the liver at the site of production, and can partially explain results from studies
in which a change in circulating insulin concentrations can drive a change in circulating
estrogen concentration with no apparent change in body fat (Zeleniuch-Jacquette et al.
2004).
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The significant variability of cancer development, essentially a progressive
genetic disease, and the interrelatedness of symptoms associated with obesity and
metabolic disease causes much debate over the impact of biomarkers in the progression
of cancer. There is a positive association between circulating estrogen concentrations on
the risk for developing postmenopausal (ER+) breast cancer, despite the low levels of
estrogens within this population. Aromatase inhibition via pharmacotherapy has become
quite common, and one of the outcomes of aromatase inhibition is to drive concentrations
of circulating estradiol well below detectable assay limits, a significant challenge to
studies attempting to address the relationships between postmenopausal estradiol
concentrations and health outcomes after primary breast cancer treatment (Rosner et al.
2013). Additionally, aromatase inhibition may significantly alter SHBG concentrations.
Several studies have identified both significant increases and significant decreases in
SHBG following aromatase inhibition (Bajetta et al. 1999, Boeddinghaus et al. 2001) and
the appropriateness of using SHBG as a surrogate measure for estradiol in
postmenopausal women is unclear. Thus, while estradiol represents a prime candidate for
the assessment of intervention efficacy (based on the high correlation with cancer risk
and recurrence), that rapidly increasing number of women taking aromatase inhibitors
and the difficulty of assessing postmenopausal estradiol concentrations may necessitate
using alternative measures, such as SHBG and estrone. This limitation will be discussed
further in chapter III.
Adipokines
The role of leptin and adiponectin in breast cancer has recently generated large
amounts of research. One contributing factor to this is the identification of leptin
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expression in mammary epithelial cells, a primary location for mutations leading to breast
cancer development. Leptin has wide-ranging systemic effects on a variety of tissues, but
is currently viewed as both a regulator of energy balance and an inflammatory adipokine.
Estrogen production in adipose tissue is highly promoted by leptin (Binai et al. 2013),
and circulating leptin levels are correlated with aromatase activity (Maccio et al. 2010).
Leptin could therefore serve as a surrogate marker for the effects of exercise on
aromatase activity in postmenopausal women taking aromatase inhibitors. These women
would not register significant levels of circulating estrogen, but may have locally active
estrogen acting in a paracrine fashion to enhance breast cancer risk. Another interesting
and potentially relevant aspect of leptin is the signaling pathway activated by the binding
of leptin to its receptor. While insulin and IGF-1 enhance cellular proliferation through
PI3K/Akt and MAPK pathways, leptin appears to enhance cell proliferation through the
JAK/STAT pathway (Sharma et al. 2006). This would therefore suggest that a mutation
residing on this pathway may not be enhanced by hyperinsulinemia but may be enhanced
by hyperleptinemia. As researchers begin to view leptin as hormone that shares some
similarity with insulin with respect to disease development and impact (however with
daily peaks and nadirs much more narrow than those of insulin), investigations into the
role of leptin as a contributor to metabolism in both health and disease are critical.
Adiponectin is also a hormone secreted from adipocytes that may play a role as a
biomarker for breast cancer development, however it appears to have an inverse
relationship with cancer risk (Liu et al. 2013). The mechanisms by which adiponectin
may influence breast cancer development are unclear, however it has been proposed to be
related to insulin and IGF-1 activity (Duggan et al. 2011). Adiponectin also displays an
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inverse relationship with circulating estrogen levels (Cleary et al. 2009), but any potential
causal interactions have not been identified. Similar to leptin, it appears that adiponectin
may work via a PI3K/Akt independent pathway, in this case through direct modification
of AMPK (Kim et al. 2009). The adipokines therefore represent a highly intriguing
secondary area of interest in studies in which the primary focus centers on insulin/IGF-1
because these hormones often alter cellular metabolism independently of the PI3K/Akt
phosphorylation cascade.
Summary of biomarkers
The current literature on biomarkers associated with physical activity and breast
cancer recurrence centers around three overlapping and interrelated pathways with two
potential alternatives. First, insulin itself may act as a potent mitogenic compound,
directly activating the PI3K/Akt pathway and potentially blocking the tumor suppressors
that regulate this pathway. Secondly, high levels of IGF-1 may stimulate cell
proliferation, and this may be in part regulated via insulin’s’ effects on IGFBP3 activity
and shared sequence and receptor homology. Finally, aromatization of androgens to
estradiol in adipose tissue represents a significant risk factor for breast cancer
development, and this process may also be modulated in part by the degree of insulin and
IGF-1 exposure. In addition to these primary mediators and moderators of breast cancer
risk, systemic low-grade inflammation and adipokines may provide alternative means by
which the environment may modify breast cancer development. In all of these cases it is
not necessarily the exposure to a specific hormone/factor that induces breast cancer, but
rather the magnitude and/or combinations of exposure. Unlike specific (and avoidable)

33	
  
	
  

carcinogens, it is virtually impossible to eliminate these hormones and factors from the
body, and in many cases it would be unwise to try and do so.
Assessing the degree of systemic exposure to biomarkers traditionally involves
measuring them at a singular, well-controlled timepoint. This is not unreasonable, and
while there may be slight variations in the majority of these hormones over the course of
the day it is typically on a relatively small order of magnitude. This is not the case
however when it comes to insulin. The role of insulin to induce glucose uptake and
initiate many of the cellular processes involved in nutrient storage require it to be highly
variable over the course of the day. Indeed, the pancreas is capable of increasing insulin
production up to 25x that of basal levels (Ferrannini, 2010), and upwards of 70% of the
insulin to which an individual may be exposed is primarily in response to a meal, as
opposed to the fasted state when insulin is generally assessed. In order to thoroughly
understand the relationship between insulin and breast cancer risk, as well as the
modification of that relationship through exercise training, it is necessary to understand
the behavior of insulin as a hormone, especially in its primary role as the regulator of
glycemic control.
Postprandial insulin and insulin supply and demand
Several epidemiological studies have identified a potential relationship between
insulin and breast cancer risk and/or risk of recurrence (Irwin et al. 2011, Goodwin et al.
2012). Most notably, Goodwin and colleagues have consistently shown over the last
decade that not only is there a relationship between circulating insulin concentrations and
breast cancer (Goodwin et al. 2009, Goodwin et al. 2002), but that immediate treatment
with the anti-diabetes drug metformin after breast cancer diagnosis leads to a
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significantly better prognosis in hyperinsulinemic women (Niraula et al. 2012, Goodwin
& Stambolic 2011). This data is consistent with an unexpected finding that individuals
taking metformin for its anti-hyperglycemic properties were somewhat less likely to
develop breast cancer (Bodmer et al. 2010). Insulin may play a role in the regulation of
cancer risk, but studies investigating this role have traditionally fit into either cellular
mechanistic studies or population-based epidemiological studies, which have potential
limitations in their applicability to case-control or randomized controlled trials.
Concentrations of insulin, as mentioned previously, do not exist as a fixed and
stable value throughout the day. Instead, insulin rises and falls due to meals given its role
as a secretory hormone responsible for nutrient uptake and metabolism. While certainly
not exclusive, the primary role of insulin in systemic physiology is glycemic control, or
the maintenance of glucose homeostasis. In skeletal muscle, this involves initiating the
translocation of GLUT-4 glucose transporters to the surface of the cell, inducing glucose
uptake (Goodyear & Kahn 1998). In the liver, insulin causes cessation of hepatic glucose
production by inhibition of gluconeogenenesis and hepatic glycogenolysis (Wahren &
Ekberg 2008). The degree of insulin required by these tissues to accomplish these tasks
represents the insulin demand, or insulin sensitivity. Given the negative health outcomes
associated with hyperglycemia, the beta cells of the pancreas are quick to modify insulin
supply to match any changes in muscle and/or liver demand.
Should insulin supply exceed insulin demand (as is often the case with pancreatic
tumors), glucose levels will decline and there is severe risk of hypoglycemia. Likewise,
should insulin supply fail to match insulin demand, hyperglycemia and Type II Diabetes
(T2D) is likely. Diagnoses of T2D have reached epidemic proportions through a
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combination of obesity- and age-associated increases in incidence and prevalence.
Estimates now suggest that by the year 2050 one in three people in America over the age
of 50 will be present some form of dysglycemia (either prediabetes or frank T2D) (Boyle
et al. 2010), making it one of the nations’ most pressing health concerns. Given the
increased prevalence of both T2D and cancer, by 2050 breast cancer survivors presenting
with prediabetes or T2D may become the norm, rather than a minority subset of the
breast cancer survivor population. The development of T2D centers on the dynamic
closed-loop relationship between insulin secretion and both hepatic and peripheral (e.g.
skeletal muscle) insulin action, and this relationship may play a role in the risk of breast
cancer recurrence.
The role of insulin in the progression of T2D
The closed-loop relationship between insulin supply and insulin demand has made
isolating the physiological mechanisms of worsening glucose tolerance difficult, however
the development of the hyperinsulinemic-euglycemic clamp “opened the loop” and
provided a direct assessment of whole body insulin sensitivity (DeFronzo et al. 1979).
This newfound ability to isolate whole body insulin demand contributed to the idea of a
singular “pathophysiology” of T2D, in which skeletal muscle insulin resistance induced
by obesity, inactivity, and/or genetic predisposition was the initial insult to glycemic
control (Bonadonna et al. 1990). To compensate for this reduced insulin action,
adaptations occur within the beta cells of the pancreas that increase circulating insulin
concentrations and “overcome” both the ineffective insulin-mediated glucose uptake and
reduced suppression of hepatic glucose production in order to maintain circulating
glucose concentrations within a tight range (Festa et al. 2006).
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Insulin-resistant individuals can thus maintain normal glucose tolerance, provided that
they maintain enough compensatory hyperinsulinemia to match the higher insulin
demand. Eventually however, some combination of genetic factors, aging and consistent
hypersecretion of insulin causes the pancreatic beta cells to fail to produce enough insulin
to match the prevailing insulin demand (Kanat et al. 2012). In this period, commonly
referred to as ‘beta cell dysfunction,’ blood glucose begins to rise into the range of
prediabetes, and the elevated blood glucose exacerbates the beta cell dysfunction. This
has led to a view of a homeostatic negative feedback loop between insulin sensitivity and
insulin secretion that is maintained until the beta cells, weary after (in some cases) years
and decades contending with elevated insulin demand, cannot maintain glycemic control,
and glucose homeostasis enters into a positive feedback loop that invariably results in the
development of T2D (DeFronzo & Abdul-Ghani 2009). While this linear disease
trajectory may be appropriate with respect to the development of T2D, several
interactions between exercise training and insulin supply/demand make T2D prevention a
more complicated situation.
Insulin demand (sensitivity)
The unique ability of insulin to both induce glucose uptake (primarily) in the
skeletal muscle and suppress glucose production in the liver manifest as two distinct
metrics of insulin demand. Given the critical nature of insulin resistance as a primary link
between obesity/inactivity and T2D, there has been much research into how insulin
resistance develops in both skeletal muscle and the liver. The specific mechanism is still
unclear, but insulin resistance in skeletal muscle appears to manifest downstream from
both the surface receptor and the upper aspects of the phosphorylase cascade (PI3K/Akt)
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(Johnson & Olefsky 2013), such that insulin binds normally to its receptor, PI3K/Akt gets
turned on, but the signal gets lost along the way to the GLUT-4 receptors and they never
translocate to the surface. Glucose uptake can also be hindered by a loss of total GLUT-4
receptors in the case of obesity and inactivity (Bienso et al. 2012). It is unclear what
molecular signal induces the compensatory increases insulin supply to overcome this
insulin resistance, however the additional insulin binding to receptors on the surface of
skeletal muscle provides enough impetus to drive enough GLUT-4 translocation to
maintain adequate glucose uptake. Since these GLUT-4 receptors are only active in the
insulin stimulated (i.e. postmeal) state, changes to skeletal muscle insulin demand have a
much larger effect on postprandial insulin secretion than on fasting insulin
secretion(Daily 2003). It is common for highly inactive people to have relatively normal
fasting insulin levels but require large amounts of insulin during and after a meal to
induce glucose uptake lower blood glucose and.
Liver insulin resistance is different from skeletal muscle in that abnormalities to
insulin demand are reflected in both fasting and postmeal glycemic regulation. In the
fasted state, the liver is responsible for producing sufficient amounts of glucose in order
to maintain adequate circulating concentrations. The importance of this task cannot be
overstated; if you do not produce glucose from the liver by creating it (gluconeogenesis)
and/or breaking down stored liver glycogen, hypoglycemia can be common and
debilitating. Hyperinsulinemia in the fasted state is therefore a reflection of the amount of
insulin required to maintain this normal production of glucose from the liver (Basu et al.
2013). Because glucose concentrations following a meal are high enough to keep the
brain operating, the role of liver insulin demand in the postmeal state shifts towards
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suppressing the (now superfluous) production of glucose. This leads to a fairly clear
distinction between the role of liver and skeletal muscle insulin sensitivity, based on the
presence or absence of elevated circulating glucose concentrations. The insulin levels
observed in the fasted state represent the interaction between liver insulin demand and
pancreatic beta cell insulin supply, whereas the insulin levels observed in the fed state are
a reflection of the interaction between; 1) liver insulin demand (to suppress endogenous
glucose production), 2) skeletal muscle insulin demand (to initiate glucose uptake) and 3)
beta cell insulin supply (Matveyenko et al. 2008). We, and others, have observed
discordance between skeletal muscle insulin sensitivity and hepatic insulin sensitivity
(Braun et al. in preparation, Faerch et al. 2010). The correlation between liver and
skeletal muscle insulin sensitivity is not strong enough that one may serve as a surrogate
for the other, and this may have wide-ranging implications on the conclusions drawn in
many studies investigating the influence of insulin and diabetes on breast cancer risk or
recurrence.
Insulin supply and beta cell function
Insulin demand is the primary driver of insulin supply, but there are several
distinct ways that the pancreas and liver can accomplish the task of meeting the demand.
Insulin, as mentioned previously, is formed in the beta cells of the pancreas through the
process of cleaving proinsulin into insulin and C-peptide. This cleaving takes place inside
the vesicles, and therefore C-peptide and insulin leave the beta cells of the pancreas in an
equimolar ratio (Polonsky & Rubenstein 1984). A certain percentage of these vesicles lie
attached to the cell membrane of the beta cells and are released extremely quickly in
response to a rise in circulating glucose, but other vesicles are located deeper within the
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beta cells and take longer to release their stored insulin in response to both glucose and
other signals, such as free fatty acids and incretins (Hatakeyama et al. 2006). This results
in a distinct secretory pattern in which insulin is released very quickly with the first
exposure of glucose (known as the acute insulin response, or AIR), followed by a second
slower phase of insulin secretion. The relationship between these phases of insulin
secretion and diabetes risk are fairly well established (Cobelli et al. 2007), however their
role in breast cancer risk or risk of recurrence is unknown.
Prior to reaching the general circulation, a portion of the insulin produced by the
pancreas is extracted and degraded by the liver in a process referred to as first-pass
hepatic insulin extraction (HE) (Campioni et al. 2009). The percentage of insulin
extracted through HE is highly variable, such that severely insulin resistant individuals
(i.e. those requiring a high degree of hyperinsulinemia to maintain glycemic control) may
extract minimal amounts of insulin (Andreev et al. 2009, Tura et al. 2001). In order to get
an accurate assessment of insulin secretion from the beta cells (beta-cell function),
interventions often use C-peptide instead of insulin to quantify changes to insulin
secretion and the effects of interventions on the pancreas. The precise metabolites and
signaling pathways that influence hepatic extraction are poorly understood, and several
researchers have noted that HE and insulin degradation in general represents a
remarkably understudied area of research (Bonnet et al. 2011). Given the importance of
the liver in relation to many of the risk factors associated with cancer development (e.g.
SHBG, IGF-1), the assessment of HE along with insulin may represent a fruitful area of
research with respect to interventions.
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To return to the study in which the relationship between insulin resistance and
biomarkers of breast cancer risk was determined based on the change in fasting C-peptide
(Fairey et al. 2003), it should now be evident that these conclusions may be an
oversimplification of the actual effect of the exercise intervention. The C-peptide
concentration reflects the function and adaptation of the beta cell and not necessarily the
action of the affector hormone (insulin). Additionally, the assessment of insulin
resistance in the fasted state may not be capturing the change to insulin demand in the
postprandial state, which may be important considering the role of exercise to modify
postmeal hyperinsulinemia and the uncertainty about total or fasting insulin exposure in
the risk for breast cancer recurrence.
Clinical role of the disruption of insulin supply and demand
In order to assess the impact of insulin supply and demand on the risk for breast
cancer, it would make the most sense to include individuals with prediabetes who display
marked hyperinsulinemia. Prediabetes exists as an intermediate metabolic state between
normal glucose homeostasis and T2D, and is primarily characterized by mild
hyperglycemia and exaggerated hyperinsulinemia. Compared to T2D, insulin levels are
higher in this prediabetic stage, and it has been recently reported that the risk for breast
cancer development is higher in individuals with prediabetes than in those with normal
glycemic control or frank T2D (Onitilo et al. 2014). Additionally, the largest magnitude
of change in insulin concentrations following exercise training is seen in individuals with
prediabetes, which is likely due to a confluence of factors associated with the
pathophysiology of T2D. Individuals with prediabetes are close to maximally insulin
resistant, however they retain the ability to secrete considerable amounts of insulin
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(Abdul-Ghani et al. 2006). Reducing insulin supply by reducing insulin demand (in the
form of exercise induced increase in insulin sensitivity) will preserve beta cell function
and significantly prolong the time in which normal circulating glucose concentrations can
be maintained (Utzschneider et al. 2004). Additionally, the reduction in insulin
concentrations in individuals with prediabetes following exercise training often
approaches 10-20% in the fasted state and 30-50% in the postprandial state (Jenkins &
Hagberg 2011, Malin et al. 2013), which may represent a significant reduction in risk of
breast cancer recurrence and warrants a more complete understanding of the precise
mechanisms involved.
Interventions to better match insulin supply and demand
Given the role of mismatched insulin supply and demand in diabetes
pathophysiology, it is not surprising that researchers have focused a large volume of
research on interventions that may better match insulin supply and demand. While
exercise training significantly increases whole body insulin sensitivity (Malin et al. 2013)
and likely leads to concomitant reductions in insulin supply, pharmacological agents such
as metformin likely exert a tissue-specific effect (Viollet & Foretz, 2013). While it is
unlikely that metformin and exercise training work together to improve specific
components of systemic insulin supply and demand (Malin et al. 2013, 2014, Jenkins et
al. 2014), it is possible that they have unique tissue specific effects. Therefore, the
purpose of Study 1 of this dissertation was to investigate the role of exercise training
and/or metformin on tissue-specific components of insulin supply and demand. This
may provide insight into the specific means by which exercise training can modify
breast cancer risk and/or improve prognosis in breast cancer survivors.
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Summary of insulin supply and demand
Insulin is the primary hormone responsible for maintaining glycemic control, and
circulating insulin concentrations have wide-ranging applicability in health and disease.
While the assessment of insulin concentrations in the fasted state may present a snapshot
of metabolic health, it is by no means exclusive and all encompassing. There is evidence
that insulin levels may play a role in cancer recurrence, however an individuals insulin
exposure may be widely discordant based on that individuals particular supply and
demand. Insulin demand can be identified through skeletal muscle, liver, fasting and
postmeal effects. Insulin supply includes not only the actions of the beta cell increasing
or decreasing secretion, but also that of the liver breaking down a certain percentage
before it reaches the general circulation. Conclusions and inferences based on
relationships between insulin supply and demand and markers for breast cancer risk may
be failing to capture areas in which hyperinsulinemia, glycemic control and breast cancer
risk overlap. Both hyperinsulinemia and insulin resistance have been suggested to be
moderators of breast cancer recurrence, however not all insulin resistance and
hyperinsulinemia are created equal. Many aspects of the interactions between
hyperinsulinemia and insulin resistance and breast cancer risk have not been thoroughly
investigated. This lack of information can have direct effects on several aspects of
glycemic control not traditionally assessed in breast cancer survivorship studies,
including those using exercise training.
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Exercise, hyperinsulinemia and breast cancer
The relatively recent obesity epidemic has triggered interest in the relationship
between physical activity, metabolic outcomes, and diseases such as cancer. As
mentioned previously, the link between physical activity and cancer development appears
to be fairly consistent across all types of solid tumor cancers (Courneya et al. 2013,
McTiernan 2003), and the consensus based on these large cross-sectional epidemiological
studies is that individuals who engage in physical activity have approximately 10-25%
lower risk of developing breast cancer than highly sedentary individuals (Ballard-Barbash
et al. 2012, Irwin et al. 2003). Additionally, several observational studies suggest that
breast cancer survivors who habitually engage in walking or other aerobic activities
reduce their risk of all cause and cancer specific death by up to 70% (Holmes et al. 2005,
Holick et al. 2008). This relationship between PA and cancer recurrence has generated
research into prospective mechanisms behind this risk reduction.
Randomized controlled trials of exercise training in breast cancer
In 2010 the American College of Sports Medicine released an evidence-based
position stand on the relationship and efficacy of exercise training to improve outcomes
related to cancer (Schmitz et al. 2010). In it, they identified 32 prospective randomized
controlled trials (RCTs) that investigated the relationship between an exercise training
program and health outcomes in breast cancer survivors. The results of these studies all
seem to suggest that exercise training in breast cancer survivors is safe and leads to
improvements in fitness and quality of life similar to those benefits seen in age and sexmatched controls. One of the limitations noted by the authors of this position stand was
the relative paucity of information with respect to metabolic outcomes. Of the 32 RCTs
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included, less than 10 collected any type of blood metabolites, and very few of those did
so with specific transdisciplinary goals in mind, such as the role of exercise training to
modify the relationship between breast cancer survivorship and CVD. Indeed, it was this
paucity of data that likely spurred on several aspects of the current Transdisiplinary
Research on Energetics and Cancer (TREC) initiative (Patterson et al. 2013(a)),
composed of several large RCTs designed to investigate the relationship between cancer
and a host of physiological variables, such as insulin resistance. Several of these TREC
projects include exercise training and/or increased PA as the means by which they
modify energetics and potentially manipulate health outcomes, including a major wing of
the project investigating the role of insulin in breast cancer (Patterson et al. 2013 (a)).
These projects were all initiated in 2011 (with study designs published) and given a fiveyear window to complete before the information will be reduced and released in a
singular document, and until 2016 we are left to speculate with respect to what they will
find. Given the relatively few published studies investigating metabolic outcomes in
breast cancer survivors it is beneficial to identify their specific methods and outcomes,
specifically highlighting any relationship between exercise, insulin/glycemic control and
markers of breast cancer risk.
One of the first studies to investigate the role of insulin to moderate the effects of
exercise in breast cancer survivors was published in 2003 by Fairey and colleagues at the
University of Alberta (Fairey et al. 2003). This study included 52 postmenopausal stage
I-III breast cancer survivors randomized into 3x/week of cycle ergometry for 15 weeks
(n=24) or control (n=28). The primary outcomes of this study were fasting insulin, IGF-1,
IGFBP and insulin resistance (assessed by homeostasis model assessment, or HOMA, the
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product of fasting insulin and glucose and an algorithmic constant). They observed no
differences in insulin or insulin resistance following the 15 weeks of exercise training,
however they did observe statistically significant decreases in IGF-1 and increases in
IGFBP3, leading to a significant change in the IGF-1/IGFBP3 ratio.
The results from this study would therefore suggest that exercise training may
have a significant impact on risk of breast cancer recurrence, however this risk reduction
does not occur as a result of a change in insulin concentrations or insulin sensitivity. This
conclusion is limited in scope however, as the effects of insulin and insulin resistance
were evaluated only through fasting insulin concentrations, which also serves as the
basis for their modeling of insulin resistance. Since exercise training manifests primarily
in reductions in postprandial insulin concentrations (as a reflection of increased skeletal
muscle insulin sensitivity), it is likely that assessing fasting insulin concentrations alone
was not enough to capture the full modifications to glycemic control brought on by the
exercise training intervention. In fact, one of the interesting aspects of this study was that
fasting insulin concentrations in the exercise group slightly increased following the
exercise training, rather than decreasing (as was expected) or staying the same (as was
the case with the control group). This was not commented upon by the researchers,
however it is not a unique finding. Other researchers have observed slight increases in
fasting insulin and/or glucose levels following the initiation of an exercise program as the
mechanisms controlling fasting insulin supply and demand attempt to adjust to
potentially large changes in postmeal insulin supply and demand (Winnick et al. 2008,
Yates et al. 2010). This behavior of fasting insulin may therefore represent a
manifestation of changes in postmeal insulin levels that were not addressed in the study.
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Ligibel and colleagues (Ligibel et al. 2008, Ligibel et al. 2009) attempted to build
on the conclusions of the previously described study by incorporating resistance training
and including a slightly larger number of participants (n=40 for the exercise group). This
study achieved remarkable control for an exercise training study in which 40 women did
supervised resistance training, and the results from this intervention suggest that this
program was enough to induce moderate changes in insulin concentrations. These
changes in insulin and insulin resistance were significant over time, and were trending
towards significance when compared to the control group. In addition to the standard
limitation of using fasting insulin concentrations as a marker for daily glycemic control,
the women in this study were remarkably metabolically healthy. While the criteria for
enrollment in this study almost exactly matched the study by Fairey et al. (mostly
postmenopausal breast cancer survivors with BMI>28 and exercising <15 min/wk), their
fasting glucose (85 mg/dL) and insulin (8 uU/mL) are in the optimal range for this
population. It is therefore possible that the results from this study may be difficult to
interpret based on the health of the participants and the relative lack of improvement to
insulin and glucose concentrations that may be gained through moderate aerobic and
resistance training. The results of this intervention may have been different had the
participants been hyperinsulinemic or prediabetic, which is a significant proportion of
overweight, inactive postmenopausal women.
At roughly the same time, Irwin and colleagues published results from the Yale
Exercise and Survivorship (YES) study, a large RCT also aimed at further establishing
the metabolic pathways by which exercise may modify cancer recurrence. Metabolic
results from this study were published in three papers (Irwin et al 2009 (a), Irwin et al.
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2009(b), Jones et al. 2013), and served as much of the basis for this proposed project. The
primary metabolic outcome investigated was the relationship between insulin, IGF-1 and
IGFBP3 following a 6-month combined supervised and home-based aerobic exercise
intervention in breast cancer survivors (Irwin et al. 2009(a)). This study is notable for its
inclusion of several key measures that were not included in the previous studies,
including an objective (albeit pedometer based) measure of PA and DEXA scanning to
assess changes in BMD, body fat and central adiposity. The women enrolled in this study
were remarkably similar to those from Fairey et al. and Ligibel et al with respect to BMI
(30), age (57 years) and activity status prior to intervention (12 min/week). Participants
fasting insulin concentrations decreased in the exercise training group (24.57 uU/mL to
22.9 uU/mL) and increased in the control group (25.69 uU/mL to 31.98 uU/mL),
however this result was not significant (p=0.08). When compared to control, the exercise
training group did have significantly lower IGF-1 concentrations following the exercise,
in support of the results found by Fairey and colleagues. In addition to the changes
observed in IGF-1 and trends towards change in insulin, this cohort also lost a significant
amount of weight and body fat compared to control, leading the researchers to conclude
that the primary impact of the exercise training on metabolic health and risk of recurrence
is through weight loss in this population. Without a thorough investigation into the
mechanisms of postmeal insulin supply and demand, that conclusion may not be
representative of the exact role an exercise induced increase in insulin sensitivity plays in
the reduction of breast cancer risk.
In addition to the direct measurement of insulin and IGF-1 the YES cohort was
evaluated for changes in inflammatory markers, including TNF-a and IL-6 (Jones et al.
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2013). While there was no role of inflammation in the overall group responses, there was
a significant change in IL-6 in those who performed >80% of the training sessions. Based
on this result and the results of several other exercise studies (Rogers et al. 2013), a
potential role of inflammation with respect to exercise induced modulation of breast
cancer recurrence risk cannot be ruled out and warrants further investigation. Absent
from these previous studies is an investigation into the role of estrogen, SHBG and the
adipokines (leptin and adiponectin). Roughly 30% of the participants of the YES study
were on aromatase inhibitors, and that may have severely complicated any potential
conclusions made with respect to the interaction between estrogen/SHBG levels and
exercise.
Other exercise training in breast cancer survivor studies
Several studies investigating the role of exercise training in breast cancer
survivors published after the 2010 ACSM position stand warrant further discussion.
Campbell and colleagues have recently completed an exercise trial in which an exercise
program similar to the one introduced by the United States Diabetes Prevention Program
(USDPP) was used in breast cancer survivors (Campbell et al. 2012), while Goodwin and
colleagues have published preliminary work on the role of metformin in breast cancer
survivors (Niralua et al. 2012), which also draws partly from the USDPP. The USDPP
was a large multi-site RTC investigating the role of a lifestyle intervention or metformin
in the prevention of the transition from prediabetes to frank T2D. This trial was a
resounding success, as the lifestyle intervention reduced the transition from prediabetes to
T2D by well over 50% and metformin was also effective at a rate of approx. 30%
(Knowler et al. 2002). The success of this program has lead to widespread follow-up
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studies, including by our lab (Malin et al. 2012). Of particular note, these follow-up
studies have shown that while both exercise (the primary driver of the changes seen in the
lifestyle group) and metformin improve metabolic health and reduce insulin
concentrations, they do so through different mechanisms. Exercise training, as mentioned
previously, induces metabolic adaptations to insulin supply and demand through skeletal
muscle, and therefore manifests most prominently in postmeal hyperinsulinemia (Kirwan
& Jing 2002), while metformin interacts primarily with the liver (McCormack et al.
2001), inducing changes to fasting insulin and glucose concentrations.
Results from Goodwin and colleagues work with metformin and breast cancer
recurrence/prognosis have been mixed. They generally support a significant reduction in
fasting insulin concentrations and insulin resistance (Niralua et al. 2012), but with
minimal effect on prognosis in those with T2D (Lega et al. 2013). Several large clinical
trials, including several arms of the TREC initiative, are underway to determine the exact
role metformin may play in reducing the risk of cancer recurrence, with the results from
these trials forthcoming. The study by Campbell et al. did not observe any relationship
between a USDPP-based lifestyle intervention composed of exercise and dietary
modification and biomarkers of breast cancer recurrence, however several limitations
may have confounded their results. First, their fasting glucose concentrations were not in
the prediabetic range (95 mg/dL) and their fasting insulin concentrations were normal
(8.9 uU/mL), potentially running into a “basement” effect where the low levels of
glucose and insulin prevent exercise training from having a measurable effect on
glycemic control, similar to Ligibel et al. Secondly, while there was considerable
reduction in insulin concentrations following the exercise training, the high degree of
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variability (+/- 9.1 uU/mL SD) in those insulin concentrations may have contributed to
the lack of significant differences in the lifestyle intervention group. Finally, as with
other studies investigating the role of exercise in breast cancer survivors, the metrics of
hyperinsulinemia and insulin resistance were derived from a fasting measure of insulin
(and glucose for the HOMA score), which may not be an appropriate reflection of the
role of exercise in the modulation of hyperinsulinemia. Several of the TREC studies
were designed to investigate the interaction between exercise training and cancer risk,
prognosis and treatment. Their study designs are consistent in that they all include
metabolic measurements, and those investigating the role of insulin are designed to
primarily reflect insulin supply and demand in the fasted state. The relationship
between fasting and postmeal insulin supply and demand and biomarkers of cancer
recurrence are unclear, and therefore study 2 will investigate the relationship using
information from the pre-intervention glucose tolerance testing and fasting
biomarkers of cancer risk taken at the same timepoint. Lack of information regarding
the effect of exercise training on postprandial hyperinsulinemia could lead to a significant
underestimation of the role of exercise training in modifying cancer risk in this
population. To address this potential confounding relationship between fasting and
postmeal insulin concentrations with cancer risk, study 3 will examine the change in
insulin supply and demand following exercise training and how that relates to the
change in cardiometabolic health in breast cancer survivors. Results from this study
should aide in the understanding of treatment-specific mechanisms, potentially
identifying situations in which reducing postmeal insulin concentrations though exercise
may be more critical than reducing fasting insulin concentrations via pharmacology, such
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as metformin. Evaluating postprandial insulin within this population takes additional
importance from the recent results from our lab that suggest that adding metformin to
exercise training blunts the effects of the exercise (Malin et al. 2012). Should changes to
postprandial rather than fasting insulin concentrations drive the beneficial adaptations to
biomarkers of breast cancer risk, breast cancer survivors who both exercise and take
metformin may actually be increasing their risk of recurrence. This well-controlled, albeit
relatively small, prospective study into the interaction between postprandial
hyperinsulinemia, exercise and breast cancer recurrence may not be enough to alter the
conclusions derived from these large generously funded multi-site RCTs, however it
could potentially serve as the basis for larger proposals investigating this relationship in
the future.
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CHAPTER III
EXERCISE TRAINING AND METFORMIN DIFFERENTIALLY IMPACT
COUPLING OF INSULIN SUPPLY AND DEMAND
Introduction
A key aspect of type 2 diabetes (T2D) prevention is the ability to appropriately
match the production of insulin with the demand of whole-body insulin resistance. Up to
70% of individuals with prediabetes (fasting and/or post-challenge glucose
concentrations above normal but below the range of frank T2D) are characterized by an
inappropriate matching of insulin secretion and sensitivity (DeFronzo & Abdul-Ghani
2011), and without lifestyle or pharmacological intervention the transition from
prediabetes to T2D is highly likely (Nijpels et al. 1996). Results from the United States
Diabetes Prevention Program suggest that both lifestyle intervention (comprised of
weight loss and increased physical activity) and the anti-hyperglycemia medication
metformin delay the transition from prediabetes to T2D (Kitabchi et al. 2005). Despite a
plausible expectation of additivity, recent evidence suggests that combining metformin
and exercise training confers no added benefit to whole-body insulin sensitivity and
markers of cardiovascular risk when compared to exercise training alone (Jenkins et al.
2012, Malin et al. 2012, Malin et al. 2013). Lifestyle interventions increase whole-body
insulin sensitivity and reduce circulating insulin concentrations, which is primarily a
result lower insulin secretion (Kahn et al. 1992). However, circulating insulin
concentrations may also be modified by insulin synthesis in the beta cells (Polonsky et al.
1994) or altered rates of insulin extraction and clearance by the liver (Escobar et al.
1999). These effects likely lie outside the closed-loop relationship between whole-body
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insulin sensitivity and compensatory insulin secretion, and may not be effectively
captured with standard tools (e.g. euglycemic clamp) and metrics (e.g. HOMA-IR) used
to evaluate changes to insulin sensitivity and secretion. Understanding the difference
between tissue-specific and whole body insulin supply and demand regulation has more
than academic importance given that preservation of beta-cell capacity is a key to
diabetes prevention. Metformin influences glycemic control through inhibition of hepatic
glucose production (Madiraju et al. 2014), and it is likely that there are other tissuespecific responses (e.g. hepatic insulin clearance) through which metformin may
influence glycemic control. Without evaluating the combined effects of exercise training
and metformin on tissue-specific markers of glycemic control (e.g. beta cell proinsulin
processing, insulin clearance) that lie outside the insulin secretion-sensitivity feedback
loop, it is possible that the utility and drawbacks of combining lifestyle interventions and
metformin to prevent or delay T2D are not fully understood.
Proinsulin, the precursor prohormone to insulin and a marker of insulin synthesis,
is primarily contained within the beta cells of the pancreas, where it is cleaved into
insulin and C-peptide prior to release into the general circulation. Elevated circulating
proinsulin concentrations represent a decoupling between glucose variations and the
synthesis and release of insulin, as proinsulin that could otherwise be used for insulin
production ‘leaks out’ into the general circulation. It is therefore not surprising that total
proinsulin concentrations, as well as the ratio between proinsulin and both insulin (PI/I)
and C-peptide (PI/C), are elevated in adults with prediabetes (Larrson et al. 1999,
Warcham et al. 1999). Additionally, hyperproinsulinemia is associated with both the
development and severity of T2D (Loopstra et al. 2011, Roder et al. 1999), and may
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serve as a link between impaired glycemic control and cardiovascular disease (Choi et al.
1999, Zethelius et al. 2002). Circulating proinsulin concentrations are reduced following
intervention with lifestyle or metformin (Kitabchi et al. 2005), but the effects of
combining the two interventions are unknown. First pass hepatic insulin extraction (HIE)
involves the degradation of insulin by the liver after secretion from beta cells but prior to
reaching the general circulation (Toffolo et al. 2006). Obese individuals and individuals
with hyperinsulinemia often display reduced HIE (Kim et al. 2007, Mittelman et al.
2000), which may partly contribute to their elevated circulating insulin concentrations.
HIE may be higher following interventions that reduce hyperinsulinemia or improve
glucose tolerance (Krogh-Madsen et al. 2014), however the impact of exercise training
and/or pharmacological interventions is unclear. As a result little is known about how
HIE changes with respect to alterations to insulin secretion and sensitivity, or the
relationship between HIE and changes in glycemic control (Krogh-Madsen et al. 2013,
Mittelman et al. 2000). Insulin clearance (IC), or the systemic breakdown of insulin,
occurs primarily in the liver (~80%) and kidney (~20%) and is also reduced in obesity
(Ader et al. 2014, Valera Mora et al. 2003) and prediabetes (Castel-Auvi et al. 2012,
Marini et al. 2014). IC may respond to pharmacologically augmented weight loss (Kim et
al. 2014) but the effects of lifestyle interventions on IC are unknown.
There is a pressing public health need to prevent T2D, and maximizing the
efficacy/precision of prevention will require evaluating the independent and interactive
effects of lifestyle and pharmacological interventions. Thus the purpose of this study was
to evaluate the effects of a 12-week exercise training and/or metformin intervention on
insulin synthesis, clearance and extraction. Given our previous work suggesting
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metformin and exercise training in combination is not more beneficial than exercise alone
with respect to cardiometabolic health (Malin et al. 2012, Malin et al. 2013), we
hypothesized that metformin would not confer any added benefit, and may even blunt,
the beneficial tissue-specific effects of exercise training on IC, HIE and proinsulin
processing.
Methods
Overview
The protocol has been previously described in detail elsewhere (Malin et al. 2012,
Malin et al. 2013). Briefly, overweight to obese sedentary women and men (Table 1) with
impaired glucose tolerance, as determined by a 75 g oral glucose tolerance test, were
randomly assigned to one of four groups: Placebo (P, n=8), Metformin (M, n=9), exercise
training plus placebo (E+P, n=9), and exercise training plus metformin (E+M, n=10).
Exclusion criteria were smoking, weight instability (> 5 kg change over previous 6
months), regular physical activity (> 60 min/wk), or contraindications to metformin. Peak
aerobic capacity (VO2peak, cycle ergometer), maximal strength (1 repetition max for key
muscle groups), and body composition (dual X-ray absorptiometry, DEXA, Lunar
Technologies, Chicago IL) were tested before and after the intervention. All participants
were verbally briefed about the study and signed informed consent documents approved
by the University of Massachusetts Amherst Institutional Review Board.
Intervention protocol
All participants were instructed to maintain baseline diet and physical activity
levels throughout the 12-week intervention, and no change in diet (3-day diet records) or
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habitual ambulation (pedometer) was observed (18). Participants were randomly
assigned to receive metformin (1000 mg twice per day separated by 8-12 hours) or an
identical placebo and further subdivided into exercise training (3 days/week, 225 total
minutes of supervised aerobic and resistance exercise) or non-training groups.
Blood collection and hyperinsulinemic-euglycemic clamp
Following 24-hours of dietary and physical activity control (meals provided to
ensure caloric and macronutrient balance) and a 10-12 hour overnight fast, blood samples
were taken from an indwelling catheter placed in an antecubital vein. Blood samples
were collected and plasma was separated in tubes containing EDTA (proinsulin, insulin
and C-peptide) and NaF (glucose) and stored at -80° for subsequent analysis. Following
the fasting blood draw a 120-minute hyperinsulinemic-euglycemic clamp (5mmol, 80
mU/m2/min) was used to determine peripheral (skeletal muscle) insulin sensitivity.
Biochemical analysis
Fasting blood glucose was determined using the glucose oxidase method (GM7
analyzer, Analox Instruments, Lunenberg MA). Fasting plasma proinsulin, insulin and Cpeptide concentrations were determined using a commercial radioimmunoassay
(Millipore, Billerica MA). The cross-reactivity of the human proinsulin RIA with insulin
and C-Peptide is <0.1%, and the cross-reactivity of the human C-Peptide RIA for total
proinsulin is <4%. The intra-assay coefficient of variation was 4.7%, and the interassay
coefficient of variation was <10%.
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Proinsulin processing, hepatic insulin extraction and insulin clearance
Total fasting proinsulin, proinsulin to insulin (PI/I) and proinsulin to C-peptide
(PI/C) ratios were calculated to depict proinsulin secretion. Hepatic insulin extraction
(HIE) was assessed using the volume-adjusted insulin to C-Peptide ratio as defined by
Cobelli and colleagues (Cobelli et al. 2007). Insulin clearance was determined during the
last 30 minutes of the clamp by dividing the insulin infusion rate by the circulating
steady-state plasma insulin concentration (SSPI), as previously used by Marini and
colleagues (Marini et al. 2014, Marini et al. 2013). Whole-body insulin sensitivity was
defined as the glucose infusion rate (M) during the last 30 minutes of the clamp divided
by the SSPI.
Statistics
Data were analyzed using R statistical software (Vienna AU 2010, http://www.Rproject.org). Baseline and group differences were evaluated using a one-way ANOVA.
Pre to post differences within groups were determined using paired t-tests. Pearson
product moment correlation coefficients were used to determine associations between
changes in proinsulin, HIE and IC as well as changes in insulin action and markers of
cardiometabolic health. Statistical significance was accepted as p<0.05.
Results
Baseline characteristics and effects of training
Baseline body weight, fitness, insulin sensitivity, and physical activity levels were
similar among groups (Table 1). As reported previously (Malin et al. 2012, Malin et al.
2013), VO2peak increased in both E+P (+18%) and E+M (+10%), and weight loss was
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greater after M (-4%) and E+M (-7%) compared with P (0%) and E+P (-0.2%). Insulin
sensitivity also higher following all treatments, and the rise in sensitivity was 25-30%
greater in E+P compared with E+M (Malin et al. 2012). While there were no changes to
fasting glucose, insulin or C-peptide in the P and M groups, there were significant
reductions in fasting plasma insulin and C-peptide following E+P and significant
decreases in fasting plasma glucose and C-Peptide in the E+M group (Table 2).
Proinsulin and proinsulin ratios
Baseline proinsulin concentrations did not differ among groups. Compared to
baseline, fasting plasma proinsulin was not different in P, M, or E+P, however proinsulin
concentrations were significantly lower following E+M (Figure 1). There were no
significant differences in the PI/I ratio or PI/C ratio across the interventions (Table 2).
There was also no significant correlation between the change in fasting proinsulin and
change in insulin sensitivity (r=-0.127, p=0.46), fasting plasma glucose (r=0.199,
p=0.25), or body fat percentage (r=0.323, p=0.64).
Hepatic extraction and insulin clearance
There were no significant changes to first pass HIE in the control group or any of
the intervention groups (Table 2). There was also no significant correlation between the
change in HIE and the change in fasting proinsulin (r=0.053, p=0.76), insulin sensitivity
(r=-0.064, p=0.96), body fat percentage(r=0.139, p=0.88) or body weight (r=-0.208,
p=0.43). Steady state plasma insulin was significantly lower in M and E+M, but there
was no difference in P or E+P (Table 2). Similarly, insulin clearance was also
significantly increased in M and E+M, and unchanged in P and E+P (Figure 2). There
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was a significant association between the change in insulin clearance and change in
insulin sensitivity (r=0.344, p=0.014), however there was no association between insulin
clearance and fitness (r=0.291, p=0.15) or body fat (r=-0.143, p=0.42).
Discussion
In this study, fasting proinsulin was significantly reduced (-24%) only after
exercise training was combined with metformin. Although not significant, the decrease
with metformin alone (-20%) was comparable in magnitude to the combined intervention.
Additionally, rates of steady state insulin clearance during a hyperinsulinemiceuglycemic clamp were also significantly greater following 12 weeks of metformin, with
or without exercise training, but not with placebo or exercise training alone. These results
surprised us because we expected insulin clearance to follow a similar pattern to that of
whole-body glucoregulatory responses, such as insulin sensitivity, which were most
strongly impacted by exercise training alone (Malin et al. 2012, Malin et al. 2013). The
decoupling of changes to proinsulin and insulin clearance from insulin sensitivity and
fasting insulin implies that metformin and exercise differentially impact the relationship
between insulin demand (tissue sensitivity) and supply (secretion).
There are several potential explanations for these results. In the current study, only the
two groups that received metformin lost weight. Weight loss drives many of the
beneficial outcomes of lifestyle or pharmacologic interventions on cardiometabolic
health/disease risk. However the driving force behind these positive changes is generally
considered to be loss of fat, particularly loss of abdominal fat (Malin et al. 2012). In our
study it was only the two exercise groups, not the metformin-only group, who lost total
and central adiposity. Therefore, a causal relationship between weight/fat loss and both
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lower proinsulin concentrations and greater steady state insulin clearance in our study is
not supported. Similarly, although whole-body insulin sensitivity was strongly associated
with higher cardiorespiratory fitness (CRF), there was no change to fasting proinsulin or
insulin clearance in the exercise-only group, which showed the largest rise in CRF. In
contrast, metformin alone caused a 20% reduction in proinsulin and a 20% increase in
insulin clearance despite no change in CRF. These results imply that changes in CRF are
not necessary to alter fasting proinsulin or insulin clearance.
It is also possible that in men and women with prediabetes, fasting hyperproinsulinemia
and reduced insulin clearance are more closely associated with fasting hyperglycemia
than hepatic or peripheral insulin resistance. If so, fasting proinsulin may only decline in
response to lowering of fasting glucose. We observed no association between change in
proinsulin and changes in fasting glucose, however it is conceivable that any relationship
between the two was obscured by the relatively modest fasting hyperglycemia at
baseline, restricting the magnitude of any declines in fasting glycemia and, therefore,
proinsulin. The only group that exhibited a statistically significant decline in proinsulin
was the E+M group, which also had a statistically significant reduction in fasting glucose
concentration.
Metformin also affects signaling pathways in the beta cell (Leclerq et al. 2004),
and can alter insulin production within the beta cells through AMPK-dependent changes
to insulin synthesis (Kefas et al. 2004, Masini et al. 2014). It is therefore possible that
metformin has a direct impact on insulin production in humans but exercise does not.
Similar reductions in both insulin and proinsulin in the metformin groups suggests that
metformin may act directly on the beta cell to lower the output of proinsulin into the
61	
  
	
  

portal vein rather than altering hepatic extraction. It is also possible that metformin
influences hepatic and renal regulation of insulin kinetics via upregulation of key insulin
degradation enzymes and possibly improvement of hepatic and renal function (Cao et al.
2014, Foretz et al. 2010) but that exercise training has a minimal effect on these
processes. Directly testing how combining exercise training and metformin impact betacell function will require animal models and cell culture work in follow-up studies.
In contrast to the effects of metformin, discord between changes in circulating insulin,
proinsulin, insulin sensitivity and insulin clearance in the exercise groups suggests that
exercise training may modify glycemic control primarily by enhancing peripheral insulin
sensitivity with consequent reductions in circulating insulin (Kahn et al. 1992). While
insulin secretion represents the primary mechanism by which circulating insulin can be
adjusted, first-pass hepatic insulin extraction may also play a significant role (Kim et al.
2007). We attempted to evaluate the effects of exercise and metformin on this tissuespecific moderator of insulin supply using the relationship between circulating insulin
and C-peptide to estimate hepatic extraction. There were no differences in fasting hepatic
extraction attributable to any of the 3 interventions. The calculation of hepatic insulin
extraction using fasting C-peptide and insulin kinetics relies on several assumptions, and
without a pre- and post-intervention glucose challenge it is hard to argue that hepatic
extraction plays no role in the interaction between exercise training and metformin. A
better understanding of how exercise training or metformin alter beta cell secretion and
circulating insulin metabolism/kinetics will require cleverly designed studies to tease
apart several interrelated processes.
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Understanding the effects of exercise or metformin on measures of glycemic
control requires considering the larger context. The hyperbolic law of insulin kinetics
suggests that coupling between insulin demand (sensitivity or resistance) and supply
(secretion and clearance) is coupled such that increasing sensitivity leads to lower
circulating insulin concentrations (Stumvoll et al. 2005). The current study suggests that
metformin, but not exercise, can change insulin synthesis/clearance without necessity for
upstream changes to insulin sensitivity. If true, there are potentially important clinical
ramifications. For example, one of the oft-cited benefits to improving insulin sensitivity
is reducing hyperinsulinemia and “resting” the pancreas to preserve beta cell function. If
lower circulating insulin is a result of changes in post-secretion insulin clearance instead
of reductions in first and/or second phase insulin secretion, there may be little or no
reduction in beta cell “stress” following exercise training. Additionally, if there is
recognized value in reducing insulin synthesis by the islets regardless of the degree of
insulin reaching the general circulation, there may be practical reasons to choose between
metformin or exercise for patients who are still able to compensate for insulin resistance
with hyperinsulinemia. The divergent impact of exercise and/or metformin on tissuespecific (e.g. proinsulin and insulin clearance) compared to whole-body (e.g. insulin
action) metrics of glycemic control suggests that the utility of selecting one treatment
versus the other, or combining both treatments, is outcome-specific.
Scaling up to the critical public health issue of preventing diabetes and
cardiovascular disease in humans, the independent and combined actions of physical
activity and/or metformin on the transition from prediabetes to T2D is difficult to predict
from studies of insulin sensitivity alone. To understand the comparative efficacy of
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physical activity, metformin or both on T2D and cardiovascular disease prevention,
studies will need to be conducted in the target population with the development of frank
T2D or cardiovascular disease as the primary outcome.
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Tables
Table 3.1: Participant characteristics
P

M

E+P

E+M

N (male)

8(2)

9(4)

9(4)

10(4)

Age (years)

49.75 ± 3.87

46.33 ± 2.57

46.22 ± 2.60

49.50 ± 1.77

Weight (kg)

94.78 ± 5.28

96.47 ± 5.26

97.3 ± 4.74

93.44 ± 4.77

Body Fat (%)

45.96 ± 3.05

42.47 ± 2.45

42.16 ± 2.31

41.43 ± 2.21

VO2Peak (mlkg-1min-1)

21.44 ± 2.32

24.18 ± 2.75

25.28 ± 2.21

27.25 ± 1.76

Fasting Glucose (mmol)

5.34 ± 0.18

5.23 ± 0.24

5.45 ± 0.25

5.86 ± 0.21

2-h Glucose (mmol)

9.36 ± 0.47

9.23 ± 0.47

10.37 ± 0.34

9.81 ± 0.49

Data presented as mean ± SEM. There were no significant differences at baseline across the four
conditions
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Table 3.2: Changes to glycemic control after intervention period
P

M

E+P

E+M

Pre

5.34 ± 0.18

5.23 ± 0.24

5.45 ± 0.25

5.86 ± 0.21

Post

5.29 ± 0.12

5.28 ± 0.25

5.41 ± 0.21

5.49 ± 0.13*

Pre

139.9 ± 28.9

152.9 ± 27.5

94.9 ± 11.5

95.6 ± 20.8

Post

149.9 ± 34.0

119.7 ± 26.3

84.5 ± 9.7*

80.3 ± 13.9

Pre

874.1 ± 151.0

1375.1 ± 142.8

1154.9 ± 195.8

1052.2 ± 96.4

Post

969.8 ± 142.3

1226.4 ± 150.7

983.2 ± 169.3*

765.8 ± 76.4*

Pre

0.15 ± 0.02

0.16 ± 0.03

0.27 ± 0.11

0.24 ± 0.04

Post

0.19 ± 0.04

0.18 ± 0.04

0.27 ± 0.08

0.19 ± 0.02

Pre

0.25 ± 0.04

0.21 ± 0.03

0.19 ± 0.03

0.17 ± 0.03

Post

0.23 ± 0.04

0.17 ± 0.04

0.21 ± 0.05

0.20 ± 0.05

Pre

71.2 ± 3.8

74.4 ± 4.0

84.4 ± 1.7

84.2 ± 3.1

Post

75.8 ± 3.2

79.5 ± 3.2

83.3 ± 2.6

79.8 ± 5.1

Pre

1462.5 ± 75.4

1474.4 ± 74.8

1494.4 ± 118.9

1449.0 ± 86.4

Post

1456.3 ± 58.6

1247.2 ± 102.7*

1295.5 ± 57.3

1199.0 ± 77.5*

Glucose (mmol/L)

Insulin (pmol/L)

C-Peptide (pmol/L)

PI/I (pmol)

PI/C (nmol/pmol)

HIE (%)

SSPI (pmol/L)

Data presented as mean ± SEM. PI/I- Fasting proinsulin/insulin ratio. PI/C- Fasting proinsulin/Cpeptide ratio. HIE-Hepatic insulin extraction. (*) Indicates significant change from baseline
(p<0.05).
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Figures

Figure 3.1: Fasting proinsulin concentrations
Data presented as mean±SEM. *Indicates significant difference from baseline (p<0.05)
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Figure 3.2: Clamp-derived insulin clearance
Data presented as mean±SEM. *Indicates significantly different from baseline (p<0.05)
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Prologue to chapters IV and V
Studies 2 and 3 (chapters IV and V) of this dissertation differ from study 1 in
terms of the population (men and women with prediabetes vs. postmenopausal breast
cancer survivors) and research techniques (euglycemic clamp vs. oral glucose tolerance
test). While this gives the appearance of two disconnected and unrelated projects, there
are several areas of overlap between the studies that are worth mentioning.
The benefits of metformin as means to restrain blood glucose concentrations have
been studied for decades, however the potential utility of metformin as a
mediator/moderator of cancer risk is a relatively novel and unexpected finding (Bodmer
et al. 2010). As with any unexpectedly fortuitous result, research has been directed
towards identifying the mechanisms behind metformin-induced reductions in cancer risk
(Chae et al. 2016) and optimally incorporating metformin into existing oncotherapy
(Grossmann et al. 2015). Metformin appears to lower blood glucose concentrations by
reducing hepatic glucose production (Madiraju et al. 2014), which leads to lower insulin
concentrations in both the fasting and the postmeal state. Exercise training primarily
regulates blood glucose through reductions in skeletal muscle insulin demand in the
postmeal state, leading to a compensatory reduction in insulin supply. It is therefore
reasonable to suspect that metformin and exercise training would have additive effects on
glycemic control, as was the hypothesis for the series of experiments by Malin et al.
(Malin et al. 2012, Malin et al. 2013). This was not the case however, as combining
metformin with exercise training did not enhance, and may have even attenuated, the
beneficial adaptations to systemic insulin supply and demand that occurred as a result of
exercise training alone. The results from study 1 support the hypothesis that exercise
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training acts to reduce diabetes risk through systemic modification of insulin supply and
demand (e.g. increased insulin sensitivity), whereas metformin may accomplish this same
task (albeit to a lesser degree) through specific modifications of insulin-sensitive tissue.
While it is tempting to expand this conclusion to encompass both exercise and
metformin-induced reductions in carcingenesis, the lack of information regarding the
relationship between changes to insulin supply and demand and cancer risk following
lifestyle or pharmacological interventions prevents such interpretation from being made.
In 2011 The National Cancer Institute, in conjunction with several research
institutions across the country, began a series of research studies known as the
Translational Research in Energetics of Cancer (TREC) project (Patterson et al. 2011).
One such study mimics the four-armed intervention used in study 1 to evaluate the
benefits of exercise training and metformin in combination on cancer recurrence. While
this may shed light on the efficacy and utility of the combined and independent effects of
each intervention as oncotherapy, the lack of information regarding the tissue vs.
systemic effects of exercise training on insulin supply and demand in both the fasted and
fed state in cancer survivors may influence the interpretation of the benefits of each
treatment on metabolic health. The purpose of studies 2 and 3 of this dissertation project
were therefore to develop a greater understanding of changes to postmeal insulin supply
and demand and the physiological mechanisms responsible for them as a result of
exercise training in cancer survivors. These small, highly controlled research studies
could therefore ‘fill in the gaps’ of large clinical trials, and by doing so guide future
clinical trials and enhance the efficacy of personalized targeted therapy to reduce the risk
of cancer and diabetes.
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CHAPTER IV
EXERCISE TRAINING LOWERS POSTMEAL, BUT NOT FASTING, INSULIN
CONCENTRATIONS IN BREAST CANCER SURVIVORS
Introduction
Women who regularly engage in physical activity have significantly lower rates
of cancer development and recurrence (Moore et al. 2016), as well as reduced rates of
cancer-specific and all-cause mortality (Ballard-Barbash et al 2012). Although the precise
mechanisms are unclear, lower circulating insulin concentrations in active women may
play a role. Insulin appears to have mitogenic effects on cancer cells, and results from
cell culture, animal model and epidemiological studies support a role for elevated insulin
concentrations (hyperinsulinemia) in the development of breast cancer (Gallagher et al.
2013) and breast cancer-specific mortality (Irwin et al. 2011). Despite a mechanistically
plausible hypothesis that lower insulin concentrations following exercise training
contribute to reduced cancer risk and improved cancer prognosis, this relationship has not
been consistently observed in breast cancer survivors. Fairey et al. first evaluated the
effects of exercise training on circulating insulin concentrations in breast cancer
survivors, and their results suggested that 24 weeks of aerobic exercise training did not
lower insulin concentrations (Fairey et al. 2003). Several subsequent exercise training
studies in breast cancer survivors also failed to observe a significant reduction in
circulating insulin concentrations or decrease in insulin resistance following 12-, 16- or
26-week exercise training interventions (Ligibel et al. 2008, Irwin et al. 2009, Campbell
et al. 2012, Guinan et al. 2013). These results are surprising, as reductions in circulating
insulin concentrations have been consistently observed following exercise training in
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other populations, including postmenopausal women (Friedenreich et al. 2011). It is
unclear why exercise training interventions in breast cancer survivors do not elicit
significant changes in circulating insulin concentrations. One plausible explanation is that
the relationship between insulin and cancer risk is obscured by the use of fasting insulin,
and metrics of insulin resistance derived from fasting insulin levels (e.g. HOMA), as the
sole representation of exercise-induced improvements in insulin action and regulation.
While the relationship between insulin and cancer is often predicated on its
anabolic and mitogenic nature, the role of insulin as a glucoregulatory hormone makes it
unique among biomarkers of cancer risk. Insulin levels rise and fall several times
throughout the day in response to meals, restraining blood glucose concentrations via
induction of skeletal muscle glucose uptake and suppression of liver glucose production.
The volume of insulin required for postmeal glycemic control can account for 50-80% of
daily insulin exposure (Basu et al. 2003), and often shows a high degree of discordance
with fasting insulin concentrations (Varghese et al. 2016). Additionally, interventions that
improve glycemic control do not do so equally across different insulin-sensitive tissues
and metabolic states. Exercise training is a potent skeletal muscle insulin sensitizer, and
is more effective at reducing postmeal than fasting insulin concentrations (Jenkins and
Hagberg 2011). In fact, while fasting insulin resistance metrics have a moderate
correlation with gold standard measures of insulin resistance, it is unclear what specific
physiological components of glucose metabolism they reflect (Reaven 2013). This
potentially makes fasting insulin and associated metrics of insulin resistance
inappropriate tools for evaluating the effects of exercise training, in which changes to
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glycemic control primarily manifest through changes to postmeal insulin action and
volume.
It is possible that studies investigating the links between exercise training and
cancer risk/prognosis underestimate the role of insulin by failing to assess changes in
postmeal insulin concentrations. To date, no study has evaluated the effects of an exercise
training program on postmeal insulin concentrations or metrics of insulin resistance that
incorporate both fasting and postmeal glucose and insulin concentrations in breast cancer
survivors. Therefore, the purpose of this study was to evaluate the effects of 12-weeks of
supervised exercise training on postmeal insulin concentrations in breast cancer
survivors, and identify any significant associations between changes in postmeal insulin
concentrations and changes in biomarkers of cancer recurrence. We expect that exercise
training will minimally change fasting insulin levels but will cause a significant reduction
in postmeal insulin concentrations. Additionally, we expect that changes in cancer
biomarkers (e.g. IGF-1, leptin, SHBG) will be more closely associated with changes to
postprandial insulin concentrations than with changes in fasting insulin concentrations.
Methods
Recruitment and participants
Seventeen breast cancer survivors were recruited from the western Massachusetts
area. Participants were between the ages of 35 and 70, and were either postmenopausal
(or had oophrectomy) as determined by questionnaire. Participants were in overall good
physical health, and were free from diabetes, heart disease and any injury that would
prevent them from engaging in exercise training. Participants reported not meeting the
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current physical activity guidelines of 150 minutes/week of moderate to vigorous
physical activity. Several participants were taking endocrine therapy for ER+ breast
cancer, including Arimidex (n=5), Tamoxifen (n=2) and Aromasin (n=1). All medication
use remained stable throughout the intervention period. All participants completed an
informed consent document approved by the University of Massachusetts Institutional
Review Board prior to starting the study.
Baseline fitness and anthropometric testing
Prior to metabolic testing, participants reported to the Energy Metabolism Lab in
the Department of Kinesiology on the University of Massachusetts campus for
determination of health history, body composition and fitness. Participants filled out a
baseline health history and fitness questionnaire, followed by measurement of their height
and weight (stadiometer and physicians scale, Detecto, Webb City, MO), blood pressure
(manual sphygmomanometer, Santa medical inc., Tustin, CA) and waist circumference
(tape measurer).
Baseline fitness levels were determined using a submaximal exercise test on a
cycle ergomter (ACSM guidelines for exercise testing and prescription, 9th ed.). After a
two minute resting period, participants were instructed to begin pedaling at an initial
resistance of 25 watts, maintaining a cadence of >60 revolutions per minute. Resistance
was increased in 25-watt increments every two minutes, and heart rate and rating of
perceived exertion (RPE) were recorded at the end of each two minute stage.
Additionally, expired gasses were continuously collected using a metabolic cart
(Parvomedics, Sandy, UT) for the determination of volume of oxygen consumption
(VO2) and respiratory exchange ratio (RER). Stages were increased until participants
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reached 80% of age-predicted maximal heart rate (HRmax). Upon completion of the test,
heart rate and VO2 responses from each stage were plotted and a linear line-of-best-fit
was used to estimate VO2peak at age-predicted HRmax. To determine body composition,
participants underwent a DEXA scan (Lunar technologies, Chicago IL) at the University
of Massachusetts Health Services Center. This test was used to determine body fat
percentage, bone mineral density as well as android (central) obesity and fat free mass
(FFM).
Fasting blood sample and oral glucose tolerance test (OGTT)
Participants entered the lab following an overnight fast for assessment of fasting
and postmeal glycemic control, as well as determination of cancer biomarkers.
Participants were asked to refrain from physical activity and maintain habitual dietary
patterns 24 hours prior to the glucose challenge. An indwelling catheter was placed in an
antecubital vein by a trained research technician, and fasting blood samples were
collected in tubes containing Sodium Fluoride (Glucose), Potassium EDTA (Insulin) and
Serum Separator (cancer biomarkers). Following the baseline blood collection,
participants consumed a 75 g oral glucose test beverage (Sundex, ThermoFisher,
Waltham MA), and additional blood samples were taken at 30, 60, 90 and 120 minutes
following glucose consumption for determination of glucose and insulin concentrations.
Blood plasma/serum was centrifuged at 3000xg, aliquoted into polypropylene cryotubes
and stored at -80 degrees for future analysis.

75	
  
	
  

Supervised exercise training intervention
All participants were required to exercise at least once a week and at most four
times a week under the supervision of study personnel at the University of Massachusetts
Department of Kinesiology exercise facility (The Body Shop, Amherst, MA).
Supervising members of the research team were responsible for recording results of the
exercise training session (e.g. heart rate, METs, RPE), as well as ensuring appropriate
exercise intensity and safety. The exercise training protocol consisted of aerobic exercise
for 45-60 minutes per session at an intensity of 65-90% HRmax. Participants were allowed
to choose between a cycle ergometer, elliptical machine and/or treadmill, and exercise
sessions on a specific machine were required to last at least 20 minutes. As fitness
improved over the course of the 12-week intervention the intensity of exercise was
increased to avoid a plateau effect, including the introduction of higher intensity
intervals. The overall goals of the exercise training program were to: 1) provide sufficient
exercise stimulus to increase in aerobic fitness, insulin sensitivity, and meet the physical
activity guidelines and induce the health benefits of exercise training, as well as 2) mimic
real-world exercise training programs most commonly used in non-laboratory situations.
Post-intervention testing
Upon completion of the 12-week exercise training period participants returned to
the lab for post-intervention assessment of glycemic control, aerobic fitness and body
composition. In order to avoid confounding the exercise training effect with acute
changes to glycemic control due to diet and/or physical activity, participants were asked
to refrain from physical activity and match (as accurately as possible) their food intake
from the 24h period prior to their baseline glucose tolerance test. All participants
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completed their final exercise training session 24-36 hours prior to post-intervention
glucose tolerance testing.
Hormone, biomarker and metabolite analysis
Several different analytical techniques were used to determine the circulating
concentrations of hormones, metabolites and biomarkers, and pre- and post-intervention
samples from each participant were assayed in duplicate on the same assay in order to
reduce inter- and intra-assay variability, respectively. Circulating glucose concentrations
were determined using the glucose oxidase method (Analox instruments, Atlanta, GA)
and an inter-assay coefficient of variability (CV) of <5%. Concentrations of insulin,
leptin and adiponectin were determined using a commercially available
radioimmunoassay (RIA, Millipore, Billerica, MA) and an interassay CV of <10%.
Concentrations of 17b Estradiol (E2), IGF-1, IGFBP3 and SHBG were determined using
high-sensitivity enzyme-linked immunosorbent assay (ELISA, R&D Systems,
Minneapolis MN) and an interassay CV of <10%.
Postmeal insulin concentrations and insulin sensitivity
In addition to the insulin concentrations at each timepoint of the oral glucose
challenge (30, 60, 90 and 120 minutes), total postmeal insulin was quantified as 1) the
highest measured insulin concentration during the OGTT (peak insulin) and 2) insulin
area under the curve (AUC) using the trapezoidal method. To estimate changes to
insulin sensitivity due to the exercise training, we used the glucose and insulin values
from the oral glucose tolerance test to determine the Composite Insulin Sensitivity Index
(C-ISI) based on the formula developed by Matsuda et al. (Matsuda & DeFronzo, 1999).
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This metric is a reflection of fasting glucose and insulin homeostasis AND the
responsiveness to a glucose load (insulin action) and has a high degree of correlation
(0.78) with the euglycemic clamp (the gold standard measure of insulin sensitivity). The
formula for the determination of C-ISI is (10,000/square root of [fasting glucose x fasting
insulin] x [mean glucose x mean insulin during OGTT]).
Statistical analysis
All statistical analyses were performed using the R statistics package and
computing language using an a priori alpha of <0.05. Paired t-tests were used to evaluate
pre- to post-intervention changes in fitness, body composition, fasting hormones,
metabolites and biomarkers as well as pre- to post- intervention differences between
single timepoints of the oral glucose tolerance test. Linear mixed models were used to
evaluate the relationship between the intervention and oral glucose tolerance over the
sequential timepoints of the test, as well as the effect of any mediators of the relationship
between exercise training and change in glycemic control (e.g. the presence or absence of
Aromatase Inhibitor). Finally, associations between biomarkers and variables of interest
were determined using Pearson product-moment correlation coefficients.
Results
Participant characteristics
Of the 17 participants enrolled in this study, two were unable to complete the
fasting and glucose challenge blood draw and were thus excluded from the results.
Additionally, one participant completed the fasting blood draw but was unable to
complete the oral glucose challenge and was eliminated from any post-challenge
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comparisons (but was included for fasting metabolite/biomarker analysis). One
participant declined the DEXA scan, and her data was therefore eliminated from body
composition analysis. A flowchart of participant recruitment and inclusion is presented in
figure 4.1, and participant characteristics are presented in table 4.1. Data are presented as
mean ± SD.
Exercise training
Participants attended an average of 34.4 ± 7.7 training sessions over the 12-week
intervention. Due to the progressive nature of the exercise training program, the average
number of training sessions attended by participants increased throughout the
intervention, with participants averaging 2.7 ± 1.1 training sessions per week during
weeks 1-4 and 3.3 ± 0.8 training sessions per week during weeks 9-12. Exercise volume
increased throughout the supervised exercise training sessions, from 141.3 ± 32.9 min/wk
during weeks 1-4 to 166.8 ± 30.6 min/week during weeks 9-12. Additionally, exercise
intensity increased over the duration of the study, from 77.4 ± 5.2% HRmax during weeks
1-4 to 85.7 ± 5.7% HRmax during weeks 9-12, for an average of 81.8 ± 5.5% HRmax over
the entire 12-week protocol. As this protocol was personalized to better encourage
attendance/compliance and mimic non-laboratory exercise prescriptions, participants
were allowed to engage in several bouts of High Intensity Interval Training (HIIT) per
week at the discretion of the trainer. Each session involved 24-30 total minutes of HIIT
activity as a component of the 45-60 minute training session, and included 4 or 5 1minute periods of high intensity (>90% Age-predicted HRmax) cycling followed by 3-5
minutes of moderate intensity (<60% Age-predicted HRmax) cycling. Participants engaged
in a total of 11.1 ± 7.8 HIIT sessions over the course of the intervention, with the
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majority occurring later in the intervention (1.6 ± 0.8 HITT sessions/week over weeks 912). A full summary of the dose of exercise (e.g. volume, intensity, duration) for the
exercise training intervention by individual response is provided in Appendix A.
Fitness, body composition and ancillary health outcomes
Participants experienced a significant increase in aerobic fitness and a significant
decrease in body weight following the intervention (Table 4.2), however this reduction in
body weight was not a result of significant reductions in body fat or fat free mass. There
was no significant association between baseline fitness and change in fitness (r=0.13,
p=0.74), nor were there any significant associations between volume of exercise
performed over the 12-week intervention period and change in fitness (r=0.18, p=0.52) or
body weight (r=0.08, p=0.94). In addition to the small but significant change in body
weight there were significant reductions in waist circumference and systolic blood
pressure, but no significant changes in fasting or postmeal blood glucose concentrations
(Table 4.2).
Cancer biomarkers
One participant had E2 concentrations below the detectable limit of the assay
(5pg/ml) and was excluded from analysis. There were no significant pre- to postintervention differences in IGF-1, IGBP3, Adiponectin or SHBG levels as a result of the
exercise training (Table 4.2), however leptin and E2 levels were significantly lower
following exercise training (Table 4.2). Surprisingly, this change in circulating leptin
concentrations was not significantly associated with change in aerobic fitness (r=0.06,
p=0.92), body composition (r=0.18, p=0.48) or any of the variables associated with
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insulin concentrations. The change in circulating E2 concentrations was not associated
with changes to body fat or other adipocyte-derived biomarkers, however there was a
significant inverse association between the change in E2 and participants average
exercise intensity (r=-0.55, p=0.04) during the 12-week intervention period (Figure 4.2).
Fasting and postmeal insulin concentrations
There were no significant differences in fasting insulin concentrations (11.4 ± 5.2
vs. 11.6 ± 5.1 uU/ml) or at timepoints 30 minutes (74.4 ± 19.8 vs. 83.2 ± 37.6 uU/ml), 60
minutes (95.8 ± 30.4 vs. 98.4 ± 23.3 uU/ml) and 90 minutes (91.3 ± 32.8 vs. 88.3 ± 29.5
uU/ml) of the glucose challenge test (Figure 4.3 A). Insulin concentrations were
significantly lower 120 minutes (2h) following glucose ingestion (68.8 ± 34.5 vs. 56.2 ±
31.9 uU/ml, p<0.05, Figure 4.3 A). There were no significant differences in insulin AUC
(301.6 ± 82.2 vs. 301.9 ± 93.6 uU/ml, Figure 4.3 B) or peak insulin concentrations during
the OGTT (107.4 ± 27.8 vs. 106.5 ± 26.5, Figure 4.3 C), nor was insulin sensitivity (3.29
± 1.76 vs. 3.27 ± 1.27, Figure 4.3 D) different following the exercise training
intervention.
Factors influencing the insulin response to exercise
There were no differences in the training response when participants were
stratified based on age, stage of cancer diagnosis or cancer receptor type. However,
women who were currently taking or had taken Aromatase Inhibitors (AIs) within the last
five years (n=6) had significantly different and opposing responses in peak insulin (11.99 (non-AI) vs +13.91 (AI) uU/mL) and insulin AUC (-24.03 (non-AI) vs +32.73 (AI)
uU/mL) compared to those women who did not take AI (N=8, Figure 4.4 A and B).
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Women who were currently or had taken AIs also displayed an opposing response in CISI (+0.39 (non-AI) vs. -1.12 (AI) Figure 4.4 C) following exercise training and a blunted
reduction in 2h insulin concentrations (-20.2 ± 15.8 vs. -2.7 ± 22.7 uU/ml, Figure 4.4 D).
This result occurred despite no significant differences in exercise training volume as well
as no differences in baseline and/or change in body weight, body composition or aerobic
fitness between the two groups. Given the role of AIs are to reduce circulating estrogen
concentrations, we then evaluated the relationship between changes to peak insulin,
insulin AUC and C-ISI and changes to basal, raw and percent change in E2. We observed
a significant negative relationship between the change in peak insulin concentrations and
the change in E2 as a result of the exercise training (r=-0.57, p=0.04, Figure 4.4).
Discussion
The mitogenic role of insulin in carcinogenesis is well established, and it is
plausible that lower insulin concentrations are one of the primary benefits of physical
activity interventions on cancer risk. Several previous exercise training interventions in
cancer survivors have failed to observe any significant differences in insulin
concentrations, however these studies were limited in scope by their use of fasting insulin
(and fasting metrics of insulin resistance) as the sole representation of insulin supply and
demand. Given the large contribution of postmeal insulin to 24-hour insulin exposure
and the relationship between exercise and postmeal insulin action, it is possible that a
comprehensive relationship between exercise training and insulin supply and demand in
breast cancer survivors has yet to be established. This goal of this study was to use the
oral glucose tolerance test, a common tool for evaluating postmeal insulin supply and
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demand, to evaluate the impact of exercise training on postmeal insulin responses in
breast cancer survivors.
Results from this study demonstrate that insulin concentrations two hours after a
glucose challenge are significantly lower following exercise training, despite no
significant change in fasting insulin concentrations. This result partially supports our
hypothesis and suggests that the relationship between cancer risk/prognosis, insulin
and/or exercise training cannot be fully determined through the use of fasting insulin
concentrations alone. While insulin may contribute to carcinogenesis, the lack of
association between fasting insulin and more established cancer biomarkers (e.g.
estrogen) and minimal or absent reductions in insulin following exercise have led to a
general consensus that insulin is a minimal contributor to the improved prognosis of
cancer survivors following lifestyle interventions (McTiernan et al. 2010). The results of
this study suggest that interventions that alter postmeal insulin concentrations (e.g.
physical activity) may have a greater impact on cancer risk reduction than previously
estimated. Additionally, comparative efficacy studies on cancer risk/prognosis (e.g.
exercise training vs. metformin) may be underestimating the potential benefits of exercise
training by selecting a primary outcome (i.e. fasting insulin) that fails to capture the full
extent of the benefits of exercise training on insulin supply and demand.
In addition to lower postmeal insulin concentrations, there were several other
areas of improved cardiometabolic health following this exercise training program that
may influence prognosis in cancer survivors. Jones et al. have suggested that low aerobic
fitness following cancer treatment contributes to the elevated risk of cardiovascular
disease observed in cancer survivors, and increasing cardiorespiratory fitness through
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exercise training may significantly reduce all-cause mortality in the years following a
cancer diagnosis (Jones et al. 2015). Our personalized and progressive exercise program
was sufficient to significantly increase cardiorespiratory fitness, while still providing the
flexibility inherent in recreational and non-laboratory based exercise programs. It is
possible that by increasing and/or varying the exercise training volume and intensity
during the intervention, participants experienced greater improvements in fitness and
enjoyment than they would have in an intervention based on fixed volume and/or
intensity. Future studies that combine mixed doses (volume, intensity, duration and
mode) of exercise in ways that mimic real-world exercise accrual are needed in order to
establish the most effective dose for both cancer prevention and the litany of detrimental
health outcomes associated with cancer treatment.
In addition to increases in cardiorespiratory fitness, we also observed significant
decreases in circulating leptin and estrogen concentrations following exercise training.
While many of the health risks associated with leptin are linked to obesity, leptin also
contributes to cancer risk by enhancing adipocyte-derived estrogen activity (Vona-Davis
& Rose 2007) and increasing cancer cell motility and invasiveness (Ando et al. 2014).
We did not observe any significant associations between the changes in leptin and body
composition or fitness. This was surprising, as lower leptin concentrations after exercise
training are often the result of exercise-induced reductions in body fat (Friedenreich et al.
2011, Abbenhardt et al. 2013). However, high intensity exercise training can reduce
circulating leptin concentrations independent of weight loss in adults with type 2 diabetes
(Balducci et al. 2010), and it is possible that the relatively high intensity of the exercise
training in the current study (85% HRmax) was enough to induce a similar beneficial
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leptin response. Given the notorious difficulty of initiating and sustaining weight loss in
older individuals (Kassier et al. 1998), identifying potential ways interventions can
reduce leptin concentrations without the requirement for weight loss may have important
clinical applicability. We also observed a small but significant reduction in circulating
estrogen concentrations, which was associated with intensity, but not volume, of exercise
training. Given the extremely low concentrations of estrogen at baseline in this
population as well as the confounding factor of AI use, it is difficult to determine whether
the minor reduction in estrogen as a result of the exercise training intervention has
clinical relevance. There is a significant relationship between elevated estrogen
concentrations and increased risk of cancer development and recurrence in
postmenopausal women (Zhang et al. 2013), and reductions in circulating estrogens have
often been cited as a major contributor to lower cancer risk (Cummings et al. 2009).
Future exercise studies in breast cancer survivors that are large enough in size to account
for the low concentrations of estrogen (especially in those taking AIs) are required before
the relationship between physical activity and estrogen in this population can be fully
understood.
Despite significant reductions in insulin concentrations 120 minutes after oral
glucose consumption, we did not observe any significant differences in insulin
concentrations at 30, 60 or 90 minutes during the OGTT, nor did we observe any change
in insulin sensitivity, insulin peak concentration or area under the insulin curve. This is
surprising, as an increase in insulin sensitivity and reduction in insulin AUC are
commonly observed following exercise training interventions in many different
populations. There are several potential reasons for this outcome that are worth
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exploration. First, most participants in this study had normal glucose tolerance and
therefore had relatively low fasting and postmeal insulin concentrations prior to
beginning the exercise training program. Given the participants were normoglycemic, it
is possible that the dose of exercise was not sufficient to reduce insulin resistance or
insulin AUC from this already low baseline. While the significant increase in fitness in
the current study suggests that the exercise dose was sufficient, we did not observe any
significant associations between change in fitness and subsequent metabolic responses.
We therefore cannot rule out the possibility that our exercise dose was sufficient to
induce physiological improvements, but insufficient to alter glucoregulatory metabolism.
A second possibility for the null effect of the insulin action response is the
potential role that endocrine therapy may play in the metabolic adaptations to exercise
training. Past/present AI users had a blunted, and in some cases opposing, response to
exercise training compared to those women not taking any endocrine therapy or taking
tamoxifen. Given the role of AI to reduce estrogen production and concentrations in
circulation, we attempted to identify any potential relationships between change in
estrogen and change in postmeal insulin in both AI and non-AI participants. We observed
a significant inverse relationship between change in estrogen concentrations and change
in peak insulin, which suggests that low or significantly reduced estrogen concentrations
may negatively impact postmeal glycemic control. This supports findings by Evans et al.
that estrogen plays a role in metabolic adaptations to exercise training in postmenopausal
women (Evans et al. 2001) and warrants further investigation into the role of estrogen
concentrations as a mediator of changes to cardiometabolic health in breast cancer
survivors following exercise.
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Exercise training represents a potent tool to improve prognosis and reduce cancer
recurrence in breast cancer survivors, however the mechanisms that explain this
relationship are unclear. As we move towards the idea of personalized oncotherapy and
precision medicine, it is important to develop a greater understanding of the relationship
between exercise training and its metabolic effects in different populations. Results from
this study suggest that while exercise training may have little impact on fasting insulin in
breast cancer survivors, it has significant effects on postmeal insulin concentrations,
albeit blunted compared to those seen in other populations. Future studies designed to
link changing insulin concentrations with cancer risk and prognosis should incorporate
measures of fasting and postmeal insulin whenever possible. It is also important for larger
studies to identify whether breast cancer survivors have a diminished postmeal insulin
response compared to non-cancer survivors. As the population of cancer survivors grows,
so too does the population of cancer survivors at risk for diabetes and cardiovascular
disease. Understanding the metabolic regulation of glycemic control and its response to
exercise in cancer survivors is necessary in order to deliver personalized lifestyle and
pharmacological interventions to this already large and growing segment of the
population.
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Tables
Table 4.1: Participant characteristics

N=15
Age (yrs)
Years post diagnosis
Stage (1-3)
ER+ (%)
Endocrine Therapy (%)
Weight (kg)
Body Mass Index (kg/m2)
Body Fat (%)
Estimated VO2peak (ml/kg/min)
Blood Pressure (mmHg)
Fasting Blood Glucose (mg/dL)
2 hour Blood Glucose (mg/dL)

Mean ± SD
59.9 ± 9.2
4.0 ± 3.5
1.67 ± 0.62
11 (73%)
7 (47%)
75.5 ± 16.4
27.6 ± 5.4
43.1 ± 9.9
25.2 ± 5.4
124.5/75.5 ± 10.7/5.2
102.0 ± 13.7
120.6 ± 21.6

Data reported as mean ± SEM.

88	
  
	
  

Table 4.2: Changes in fitness, body composition, health and biomarkers

Baseline
Post-training
Change
p-value
Fitness, body composition and cardiometabolic health
Weight (kg)
75.5 ± 16.4
74.5 ± 15.8*
-1.0
0.04
BMI (kg/m2)
27.6 ± 5.4
26.9 ± 5.2*
-0.9
0.03
Body fat (%)
43.1 ± 9.9
42.6 ± 9.7
-0.5
0.31
WC (cm)
91.2 ± 11.9
88.6 ± 10.1*
-2.6
0.02
Android obesity (%)
48.1 ± 11.9
47.2 ± 11.1
-0.9
0.76
2
BMD (g/cm )
1.16 ± 0.11
1.16 ± 0.11
-0.0
0.94
FFM (kg)
42.8 ± 4.9
42.5 ± 4.5
-0.3
0.88
Est. VO2peak (ml/kg/min)
25.2 ± 5.4
27.7 ± 5.0*
+2.5
<0.01
Fasting glucose (mg/dl)
102.0 ± 13.7
99.1 ± 11.8
-2.9
0.19
2h glucose (mg/dl)
120.6 ± 21.6
115.5 ± 20.4
-5.1
0.54
Systolic BP (mmHg)
124.5 ± 10.7
120.2 ± 13.1*
-4.3
0.03
Diastolic BP (mmHg)
75.5 ± 5.2
73.8 ± 4.9
-1.7
0.10
Cancer-relevant biomarkers
Insulin (uU/mL)
11.4 ± 5.4
11.6 ± 5.1
+0.2
0.79
Leptin (ng/mL)
30.8 ± 19.3
23.8 ± 13.0*
-7.0
0.03
Adiponectin (ng/mL)
649.2 ± 208.1
622.8 ± 241.9
-26.4
0.63
E2 (pg/mL)
12.9 ± 6.3
10.2 ± 3.4*
-2.7
0.04
SHBG (nmol)
66.2 ± 47.4
64.4 ± 41.5
-1.8
0.70
IGF-1 (ng/mL)
31.6 ± 8.4
33.1 ± 9.8
+1.5
0.45
IGFBP3 (nmol)
70.3 ± 6.7
70.1 ± 8.2
-0.2
0.95
Data reported as mean ± SD. BMI= Body Mass Index, WC= Waist circumference,
BP=Blood pressure, E2= 17b-estradiol, SHBG= Sex hormone binding globulin
*p<0.05
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Figures

	
  
Figure 4.1: Participant enrollment and intervention completion
Data from participants who did not complete the fasting blood draw were excluded from analysis.
Data from participants who completed the fasting blood draw but not the OGTT were excluded
from all comparisons between intervention outcomes and OGTT-derived metrics (e.g. postmeal
insulin)
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Figure 4.2: Association between estradiol and exercise intensity and change in Estradiol
There was a significant negative association between the exercise intensity (% age-predicted
HRmax) throughout the 12 week exercise training intervention and the change in circulating 17-B
estradiol (E2) concentrations.
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Figure 4.3: Postmeal insulin responses
(A)- Insulin concentrations at each timepoint of the glucose challenge. (B)- Composite insulin
sensitivity index (C-ISI). (C) Insulin area under the curve (AUC). (D) Peak insulin
concentrations. Data presented as Mean ± SEM. *p<0.05
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Figure 4.4: Postmeal insulin responses in women with a history of aromatase inhibitor (AI) use
(A)- Change in peak insulin concentration recorded during OGTT. (B)- Change in insulin area
under the curve (AUC). (C)- Change in insulin sensitivity (C-ISI). (D)- Change in 120 min (2h)
insulin concentrations. Data presented as mean ± SEM. (*) denotes significant difference
between AI and Non-AI response (p<0.05)
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Figure 4.5: Relationship between change in estrogen and change in peak insulin
Relationship between change in 17-b estradiol and change in peak insulin following exercise
training
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CHAPTER V
CHANGES TO INSULIN SUPPLY AND DEMAND MAY BE BLUNTED
FOLLOWING EXERCISE TRAINING IN BREAST CANCER SURVIVORS
Introduction
As the population of the United States increases in age, so too does the number of
women diagnosed with breast cancer. In addition to the increase in breast cancer
prevalence, better screening and treatment methods have greatly increased the survival
rate and longevity of breast cancer survivors (Bray et al. 2004). Interventions designed to
improve prognosis in cancer survivors primarily focus on preventing cancer recurrence,
however breast cancer survivors also face higher rates of diabetes and heart disease
compared to age and BMI-matched non-cancer survivors (Hooning et al. 2007). While
cancer-specific mortality is the leading cause of death in the decade following a cancer
diagnosis, all-cause mortality (primarily as a result of cardiometabolic disease) eventually
surpasses cancer-specific mortality as the leading cause of death in cancer survivors
(Bardia et al. 2012). As the number of breast cancer survivors increases, precision
interventions designed to prevent cardiometabolic disease in cancer survivors may be just
as important as interventions to prevent cancer recurrence.
One common physiological component that may link cancer and cardiometabolic
disease is insulin resistance and the subsequent increase in insulin supply required to
maintain glycemic control (Belardi et al. 2013). Insulin has anabolic and mitogenic
properties, and hyperinsulinemia may enhance carcinogenesis (Gallagher et al. 2013) and
contribute to poor prognosis (Irwin et al. 2011) in breast cancer survivors. Prior studies
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investigating the role of insulin and insulin resistance as a mediator of breast cancer risk
and prognosis have primarily measured insulin in the fasted state, or used metrics of
insulin resistance that are derived from fasting glucose and insulin concentrations. The
mechanisms behind insulin resistance and hyperinsulinemia are complex however, and
represent a delicate balance of tissue-specific insulin demand (e.g. skeletal muscle insulin
sensitivity) matched by the appropriate volume of insulin supply (e.g. insulin secretion)
that will maintain blood glucose concentrations within a relatively tight physiological
range. Tissue-specific insulin demand changes throughout the day in response to meals,
and there can be a high degree of discordance between insulin demand and supply in the
fasted state compared to the fed state, both within (Faerch et al. 2008) and between
(Varghese et al. 2016) different populations.
Exercise training is often recommended to cancer survivors in order to counter the
detrimental effects of cancer treatment, prevent cancer recurrence and improve
cardiometabolic health (Lahart et al. 2015). One of the oft-cited benefits of exercise
training is reduced insulin resistance (Colberg et al. 2010), and this lower insulin demand
may be beneficial for cancer survivors by reducing insulin supply and thus lowering
mitogenic load. Several previous exercise training studies in breast cancer survivors have
evaluated insulin resistance through the use of fasting glucose and insulin homeostasis
modeling (HOMA), and found no significant changes to insulin sensitivity (Ligibel et al.
2008, Guinan et al. 2013). While HOMA scores effectively characterize insulin resistance
in large populations, the failure of HOMA scores to account for changes to postmeal
glycemic control makes them inadequate tools for evaluating changes to insulin supply
and demand following interventions that significantly affect postmeal insulin resistance,
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such as exercise training (Wallace et al. 2004). Given that 50-80% of total daily insulin
exposure (and thus mitogenic load) can occur in response to meals (Reaven 1979), a
more comprehensive evaluation of the changes to insulin resistance and insulin secretion
in breast cancer survivors may have significant implications for public health and cancer
prognosis.
Compared to other populations, it is possible that chemotherapy-induced
impairments to aerobic fitness and glycemic control (Jones et al. 2015), increased
sedentary behavior (Sabiston et al. 2015), and the use of endocrine therapies designed to
lower estrogen concentrations all contribute to fundamentally different adaptations to
insulin supply and demand in breast cancer survivors following exercise training. The
purpose of this study was therefore to use an oral glucose challenge to evaluate the
effects of a personalized 12-week exercise training program on systemic and tissuespecific metrics of insulin resistance, insulin secretion and other aspects cardiometabolic
health in postmenopausal breast cancer survivors. Additionally, exercise training can
reduce fatigue and enhance quality of life (Demark-Wahnefried et al. 2015), however the
relationship between these subjective measures of health and well-being and changes to
glucoregulatory control are unknown. We expect that exercise training will increase
insulin sensitivity, decrease insulin secretion and improve both beta cell insulin
processing and function in a dose-dependent fashion, however this response may be
blunted in those breast cancer survivors with low circulating estrogen concentrations.
These improvements in cardiometabolic health would also be significantly associated
with reductions in fatigue and increases in quality of life, suggesting a potential link
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between the physiological and subjective/psychological benefits of exercise training in
breast cancer survivors.
Methods
NOTE: Participants in this study were the same as those in study 2 (Chapter IV), and
underwent similar testing and exercise training protocol. Several aspects of the methods
as well as some results (e.g. estimated VO2peak, E2 concentrations) are integral to both
studies and are reported in both Chapter IV and V in order to facilitate understanding and
enhance continuity.
Participants and recruitment
Seventeen breast cancer survivors were recruited from the Western Massachusetts
area. In order to qualify for the study participants had to be postmenopausal (or have an
oophrectomy) as determined by questionnaire, and completed primary breast cancer
treatment greater than 6 months but less than 10 years ago. Additionally, participants
were free from any diagnosed cardiometabolic disease or medications that would
interfere with carbohydrate metabolism. Participants taking anti-depressants (n=3),
cholesterol- (n=1) or blood pressure lowering medications (n=2) remained on a stable
dose throughout the intervention period. Participants who were prescribed aromatase
inhibitors (n=6) or selective estrogen receptor modulators (n=2) were asked to remain at a
similar dose and regimen throughout the duration of the study.
Baseline fitness and body composition
Prior to metabolic testing, participants reported to the Energy Metabolism Lab in
the Department of Kinesiology on the University of Massachusetts campus for
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determination of health history, body composition and fitness. Participants filled out a
baseline health history and fitness questionnaire, followed by measurement of height and
weight (stadiometer and physicians scale, Detecto, Webb City, MO), blood pressure
(manual sphygmomanometer, Santa medical inc., Tustin, CA) and waist circumference
(tape measurer).
Baseline fitness levels were determined using a submaximal exercise test on a
cycle ergomter (ACSM guidelines for exercise testing and prescription, 9th ed.). After a
two minute resting period, participants were instructed to begin pedaling at an initial
resistance of 25 watts, maintaining a cadence of >60 revolutions per minute. Resistance
was increased in 25-watt increments every two minutes, and heart rate and rating of
perceived exertion (RPE) were recorded at the end of each two minute stage.
Additionally, expired gasses were continuously collected using a metabolic cart
(Parvomedics, Sandy, UT) for the determination of volume of oxygen consumption
(VO2) and respiratory exchange ratio (RER). Stages were increased until participants
reached 80% of age-predicted maximal heart rate (HRmax). Upon completion of the test,
heart rate and VO2 responses from each stage were plotted and a linear line-of-best-fit
was used to estimate VO2peak at age-predicted HRmax. To determine body composition,
participants underwent a DEXA scan (Lunar technologies, Chicago IL) at the University
of Massachusetts Health Services Center. This test was used to determine body fat
percentage, bone mineral density as well as android (central) obesity and fat free mass
(FFM).
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Fatigue, self-efficacy and quality of life
Prior to metabolic testing, participants filled out several questionnaires to
determine their current subjective levels of fatigue, general and exercise self-efficacy and
quality of life (QoL). Total of fatigue, self-efficacy and QoL, as well as specific
components of fatigue and QoL, were determined by evaluating the responses to the
entire questionnaire as well as subscore analysis.
Piper fatigue scale (PFS):The piper fatigue scale is a series of 22 validated (Piper et al.
1998) questions in which a seven point likert scale is used to evaluate current fatigue
levels over the span of days, weeks and months. In addition to overall fatigue, the PFS
has four subscales comprised of groupings of the questions to address specific
components of subjective fatigue. This includes: behavioral impact/severity of fatigue,
affective meanings of fatigue, sensory, and the impact of fatigue on cognition/mood.
General Self-Efficacy: General self-efficacy was determined using a 10-question test with
four point likert scale responses validated by Luszczynska et al. (2005).
Barriers to Self-Efficacy (BARSE): The barriers to self efficacy scale is a series questions
validated in breast cancer survivors (Awick et al. 2016) in which a five- or seven-point
likert scale is used to determine the barriers that are keeping individuals from engaging in
regular physical activity.
Exercise Self-Efficacy: Exercise self-efficacy was determined using an 8-question test
developed by McCauley (1993). Participants answered all questions on a 10 point likert
scale and both total and single questions were used.
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European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30:
Health and QoL was determined using the EORTC QLQ-C30, a quality of questionnaire
designed for cancer patients and survivors. This questionnaire asks a series of 28 specific
cancer-related questions on weekly QoL on a 4-point likert scale, and two questions
regarding overall health and QoL on a seven point likert scale.
Oral glucose tolerance test (OGTT)
Participants entered the lab following an overnight fast for assessment of fasting
and postmeal glucose homeostasis. Participants were asked to refrain from physical
activity and maintain habitual dietary patterns in the 24 hours prior to the glucose
challenge. An indwelling catheter was placed in an antecubital vein by a trained research
technician, and fasting blood samples were collected in tubes containing Sodium Fluoride
(Glucose), Potassium EDTA (Insulin, C-Peptide, Proinsulin, Triglyceride and Free Fatty
Acid) and Serum Separator (E2). Following the baseline blood collection, participants
consumed a 75 g oral glucose test beverage (Sundex, ThermoFisher, Waltham MA), and
additional blood samples were taken at 30, 60, 90 and 120 minutes following glucose
consumption for determination of glucose and insulin concentrations. Blood samples
were centrifuged at 3000xg, aliquoted into polypropylene cryotubes and the
plasma/serum was stored at -80 degrees for future analysis.
Exercise training
All participants were required to exercise at least once a week and at most four
times a week under the supervision of study personnel at the University of Massachusetts
Department of Kinesiology exercise facility (The Body Shop, Amherst, MA).
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Supervising members of the research team were responsible for recording components of
the exercise training session (e.g. heart rate, METs, Rating of Perceived Exertion), as
well as ensuring appropriate exercise intensity and safety. The exercise training protocol
consisted of aerobic exercise for 45-60 minutes per session at an intensity that would
elicit a heart rate between 60-80% of maximal heart rate. Specific details of the exercise
training intervention are provided in the methods section of chapter IV as well as the
appendix.
Hormone and metabolite analysis
Several different analytic techniques were used to determine the circulating
concentrations of hormones, metabolites and biomarkers, and pre- and post-intervention
samples from each participant were assayed in duplicate on the same assay in order to
reduce inter- and intra-assay variability. Circulating glucose and triglyceride
concentrations were determined using the glucose and triglyceride oxidase method
(Analox instruments, Atlanta, GA) and an inter-assay coefficient of variability (CV) of
<5%. Concentrations of insulin, C-Peptide, proinsulin and leptin were determined using a
commercially available radioimmunoassay (RIA, Millipore, Billerica, MA) and an
interassay CV of <10%. Concentrations of Free Fatty Acids were determined using an
Enzyme linked colormetric assay (Sigma Aldrich, St. Louis MO) and Estradiol
concentrations were determined using high-sensitivity enzyme-linked immunosorbent
assay (ELISA, R&D Systems, Minneapolis MN) and an interassay CV of <10%.
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Systemic and tissue-specific components of insulin supply and demand
Beta-cell insulin processing: Beta cell insulin processing was evaluated using pre- and
post-intervention determination of fasting proinsulin as well as proinsulin area under the
curve (AUC). Additionally, the ratio of Proinsulin to C-Peptide (PI/C) normalized to CPeptide was used as a reflection of insulin processing. This ratio has been associated with
diabetes risk (Halfner et al. 2008).
Skeletal muscle metabolic (glucose) clearance rate: Skeletal muscle glucose uptake was
estimated using the Metabolic Glucose Clearance Rate (MCR) derived by Stumvoll et al.
(Stumvoll et al. 2000). This metric estimates the degree by which insulin can induce
skeletal muscle uptake, and is therefore primarily a reflection of peripheral insulin
sensitivity without the confounding effects of basal insulin supply and demand. The
MCR has a high correlation with the glucose disposal rate determined by the euglycemic
clamp (0.80) and is derived from the equation (18.8 - (0.271 x BMI) – (0.0052 x Ins120)
– (0.27 x Glu90)).
Insulin supply: Insulin supply was comprised of three specific components. First, the
Insulinogenic Index0-30 (IGI0-30), which represents first phase insulin secretion and is
determined by dividing the increase in C-Peptide over the first 30 minutes of the OGTT
by the ambient glucose concentration over that same timeframe. In addition to the
commonly used IGI0-30, we also determined IGI60-120 in a similar fashion in order to
evaluate second phase insulin secretion. Finally, the percent first pass hepatic insulin
extraction (HIE) was evaluated at each timepoint and over the entire OGTT through the
use of insulin and C-Peptide area under the curve ((1-AUCI/AUCC)* 100) and adjusted
for body volume based on the calculations developed by Cobelli and colleagues (Cobelli)
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Insulin demand: Whole body insulin sensitivity was estimated using the Composite
insulin sensitivity index (C-ISI) developed by Matsuda and DeFronzo (Matsuda &
DeFronzo 1999). This metric is a reflection of both hepatic and peripheral insulin
demand, and is derived from measures in both the basal state and after a carbohydrate
load. C-ISI has a high correlation (0.68) with the gold standard measure of insulin
sensitivity (euglycemic clamp) and is derived from the equation (10,000/square root of
[fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]).
Beta-cell function/matching of supply and demand: Beta cell function was determined
using the Disposition index (DI), or the product of whole body insulin sensitivity (C-ISI)
and both first- (IGI0-30) and second- (IGI60-120) phase insulin secretion (IGI0-30). This
metric is based on the hyperbolic relationship between insulin sensitivity and secretion
(Kahn et al. 1992), and is typically used to identify situations where an individual risks
the development of diabetes by failing to match a reduction in insulin sensitivity with a
change in secretion. As a change in sensitivity should be matched with an change in
secretion of the opposite magnitude, the product of insulin supply and demand should be
similar regardless of the effects of an intervention, and a change in the DI represents a
change in the appropriate matching of insulin supply and demand.
Statistical analysis
All statistical analyses were performed using the R statistics package and
computing language and an a priori alpha of <0.05. Paired t-tests were used to evaluate
pre- to post-intervention changes in fitness, body composition, fasting hormones,
metabolites and biomarkers as well as pre- to post- intervention differences between
single timepoints of the oral glucose tolerance test. Linear mixed models were used to
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evaluate the relationship between the intervention and oral glucose tolerance over the
sequential timepoints of the test, as well as the effect of any mediators of the relationship
between exercise training and change in glycemic control (e.g. the presence or absence of
Aromatase Inhibitor). Finally, associations between biomarkers and variables of interest
were determined using Pearson product-moment correlation coefficients.
Results
Participant characteristics
Fifteen participants completed the study protocol, including fitness and
anthropometric testing, subjective fatigue, self efficacy, QoL, blood analysis and exercise
training. Indwelling catheter failure led to an incomplete OGTT for one participant, and
thus this participant was included for the exercise training and basal blood parameters but
not for the metrics of insulin supply and demand. Participant characteristics are included
in table 5.1.
Exercise training
Participants attended 34.4 ± 7.7 training sessions, or 2.8 sessions/wk, and
averaged 156.9 ± 30.6 minutes/wk of monitored exercise over the course of the 12-week
intervention period. Data from the exercise training intervention can be found in the
results section of chapter IV as well as the appendix.
Fitness and body composition
Aerobic fitness significantly increased as a result of the exercise training
intervention (25.2 ± 5.4 vs. 27.7 ± 5.0 ml/kg/min, p<0.05). This represents a percent
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change of +12.9 ± 3.2% over baseline. While participants experienced a significant
reduction in weight (74.3 ± 15.5 vs. 73.2 ± 15.3 kg, p<0.05) and BMI (27.2 ± 5.2 vs. 26.8
± 5.1 kg/m2, p<0.05), this was not a result of a significant change in body fat. Fitness and
body composition results are presented in Table 5.2.
Markers of cardiometabolic health
Hormones and metabolites that both reflect and regulate cardiometabolic health
are included in Table 5.2. There were no significant changes in fasting glucose or
glycemic responses to a glucose load. While there were no significant changes in
circulating triglycerides or free fatty acids, there were significant reductions in leptin and
17-b estradiol (E2) concentrations as a result of the exercise training intervention (Table
5.2).
Metrics of insulin supply and demand
There were no significant differences in metrics of beta-cell processing
(Proinsulin, PI/C), however there was a significant increase in estimated skeletal muscle
glucose clearance rate (5.7 ± 1.8 vs. 7.2 ± 1.8, mmol*pmol*kg/m2 p<0.05) as a result of
the exercise training intervention (figure 5.1). There were no significant differences in
insulin secretion/supply (IGI0-30, IGI60-120, HIE) or insulin sensitivity (C-ISIS) or beta cell
function/matching of insulin demand and supply (DI, table 5.3).
Self-Efficacy, fatigue and quality of life questionnaires
There were no significant differences in general, exercise or barriers of selfefficacy as a result of the intervention. Subscore analysis revealed significant reductions
in fatigue severity (18.5 ±13.5 vs. 11.2 ±8.8, Figure 5.2 A) as well as the impact of
106	
  
	
  

fatigue on cognition and mood (23.5 ± 10.1 vs. 19.0 ± 8.7, Figure 5.2 B). Additionally
question 1 of the PFS, an independent question not included in subscore and total
analyses regarding duration of fatigue on a six point likert scale (Months, Weeks, Days,
Hours, Minutes, and Seconds) was significantly lower following exercise training ( 3.2 ±
2.3 vs. 1.9 ± 1.6 Figure 5.3 C). There were no significant differences in cancer-specific
symptoms or fatigue as determined by the EORTC- QLQ C-30, however participants had
a significant improvement in the QoL subscale (5.3 ± 1.0 vs. 5.9 ± 0.9 Figure 5.3 D) as a
result of the exercise training. Neither the reductions in fatigue nor the improvements in
quality of life were significantly associated with any changes in the primary physiological
(e.g. estimated VO2peak) or metabolic (e.g. C-ISI) outcomes.
Discussion
The goal of the current study was to investigate the effects of 12 weeks of
personalized exercise training on the components of fasting and postprandial insulin
secretion and sensitivity in breast cancer survivors. The exercise training program used in
the current study was effective at increasing physical activity levels, which lead to a
modest but significant reduction in weight and a significant increase in aerobic fitness.
We also observed significant reductions in leptin and estrogen concentrations and an
increase in skeletal muscle glucose clearance rate, which suggests that the exercise
training in this study was of sufficient dose to induce peripheral adaptations in adipocytes
and skeletal muscle. We also observed a significant reduction in fatigue and increase in
quality of life. Despite improvements to fitness, fatigue, adipokine function and skeletal
muscle, the intervention had a minimal effect on many of the systemic components of
insulin supply and demand, such as insulin resistance and beta cell function. This result is
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surprising, given that an increase in skeletal muscle insulin sensitivity and compensatory
reduction in insulin secretion to maintain glucose homeostasis is commonly observed in
exercise training interventions (Malin et al. 2012, Kirwan & Jing, 2002).
There are several possible explanations for the lack of changes to insulin supply
and demand following exercise training, which may have both scientific and clinical
relevance. First, it is possible that the exercise dose applied in this current intervention
was not sufficient to induce changes to liver and pancreatic function that contribute to
overall regulation of insulin supply and demand. Participants in this study exercised at a
relatively high intensity and volume compared to other studies within this population, and
therefore the most likely contributor to a dose-dependent lack of effect may be the
duration of exercise training. While unlikely, it is possible that metabolic adaptations are
delayed in breast cancer survivors, and a 12-week exercise intervention that would be
effective in many other populations is not of sufficient duration to induce changes to
glycemic control.
A second potential explanation for the lack of observed changes to insulin
secretion, insulin sensitivity and beta cell function in the current study is that baseline
fasting and postmeal glucose concentrations were not impaired. Most of the OGTTderived metrics for evaluating insulin supply and demand incorporate changes to blood
glucose as a component, and it is possible that the lack of change in glucose
concentrations may have obscured some of the underlying mechanisms responsible for
regulating glycemia. Future studies in breast cancer survivors that include women with
prediabetes and/or evaluate insulin supply and demand via gold-standard techniques (e.g.
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euglycemic clamp) are needed to help address these potential confounding effects of
exercise training on cancer and cardiometabolic disease prognosis in this population.
Finally, it is possible that menopause induces physiological changes that blunt or
abrogate many of the metabolic adaptations to exercise training, and this effect is
exacerbated in postmenopausal breast cancer survivors. Cardiometabolic health declines
across the stages of the menopause (El Khoudary et al. 2012), and postmenopausal
women have significantly impaired cardiovascular adaptations to both acute (Serviente et
al. 2016) and chronic exercise training (Tenzi et al. 2013) compared to premenopausal
controls. This cardiovascular response may be partially explained by the requirement of
estrogen for exercise-induced improvements in endothelial function (Moreau et al. 2013),
however the role of estrogen as a mediator/moderator of both diabetes pathophysiology
and changes to glucoregulatory metabolism following exercise training is unclear.
Postmenopausal women taking exogenous estrogen appear to have significantly reduced
risk of diabetes and prediabetes development (van Genugten et al. 2006), and combining
exogenous estrogen with exercise training appears to improve insulin sensitivity to a
greater degree than exercise alone in postmenopausal women (Evans et al. 2001). It is
therefore possible that the low circulating estrogen concentrations in postmenopausal
breast cancer survivors, especially those on estrogen-lowering therapy (e.g. aromatase
inhibitors), are directly increasing the risk of diabetes and blunting the improvements to
insulin supply and demand following exercise training. While we observed a significant
reduction in estrogen concentrations as a result of the exercise training, there were no
significant associations between baseline or change in estrogen and any of the metrics of
insulin supply and demand. Estrogen concentrations were very low (<15 pg/ml) however,
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and OGTT-derived glucoregulatory metrics may not be precise enough to accurately
reflect these relationships.
As the number and longevity of breast cancer survivors increases, the potential
role of estrogen to both increase the risk of cancer recurrence and decrease the risk of
cardiometabolic disease may have wide-ranging clinical implications. Exercise training
reduces the risk of both cancer recurrence and cardiometabolic disease, which may be of
great importance in breast cancer survivors with high diabetes risk taking estrogen
lowering medications. In order to develop personalized interventions for breast cancer
survivors at risk for cardiometabolic disease, there is a pressing need to identify potential
areas of overlap between cancer and cardiometabolic disease and their systematic and
tissue-specific response to lifestyle interventions.
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Tables
Table 5.1: Participant characteristics

N=15
Age (yrs)
Years post diagnosis
Stage (1-3)
ER+ (%)
Endocrine Therapy (%)
Weight (kg)
Body Mass Index (kg/m2)
Body Fat (%)
Estimated VO2peak (ml/kg/min)
Blood Pressure (mmHg)
Fasting Blood Glucose (mg/dL)
2 hour Blood Glucose (mg/dL)
Data presented as mean ± SEM

Mean ± SD
59.9 ± 9.2
4.0 ± 3.5
1.67 ± 0.62
11 (73%)
7 (47%)
75.5 ± 16.4
27.6 ± 5.4
43.1 ± 9.9
25.2 ± 5.4
124.5/75.5 ± 10.7/5.2
102.0 ± 13.7
120.6 ± 21.6
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Table 5.2: Changes in fitness, body composition and cardiometabolic health

Baseline
Fitness and body composition
Weight (kg)
75.5 ± 16.4
BMI (kg/m2)
27.6 ± 5.4
Body fat (%)
43.1 ± 9.9
WC (cm)
91.2 ± 11.9
Est. VO2peak
25.2 ± 5.4
(ml/kg/min)
Cardiometabolic health
Fasting glucose (mg/dl) 102.0 ± 13.7
2h glucose (mg/dl)
120.6 ± 21.6
Glucose AUC (mg/dl)
599.2 ± 134.5
Leptin (ng/mL)
30.8 ± 19.3
E2 (pg/mL)
12.9 ± 6.3
Free Fatty Acid (mmol)
0.92 ± 0.37
Triglycerides (mg/dl)
105.4 ± 34.9
Systolic BP (mmHg)
124.5 ± 10.7
Diastolic BP (mmHg)
75.5 ± 5.2

Post-training

% Change Significance

74.5 ± 15.8*
26.9 ± 5.2*
42.6 ± 9.7
88.6 ± 10.1*
27.7 ± 5.0*

-1.4
-2.3
-1.3
-2.0
+12.9

p=0.04
p=0.03
NS
p=0.02
p<0.01

99.1 ± 11.8
115.5 ± 20.4
569.0 ± 76.8
23.8 ± 13.0*
10.2 ± 3.4*
0.77 ± 0.40
98.5 ± 29.8
120.2 ± 13.1*
73.8 ± 4.9

-2.8
-4.2
-7.9
-22.7
-20.9
-16.5
-6.6
-3.6
-3.0

NS
NS
NS
p=0.03
p=0.04
NS
NS
p=0.03
NS

BMI= Body Mass Index, WC=Waist Circumference, BMD=Bone Mineral Density,
FFM=Fat Free Mass, E2= 17b Estradiol, BP=Blood Pressure, Data presented as Mean
± SD (*) p<0.05
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Table 5.3: Changes in metrics of glycemic control

Baseline
Post-Intervention
Change p-value
Fasting PI (pmol)
11.3 ± 4.6
10.7 ± 3.6
-0.6
0.4
PI AUC (pmol)
221.1 ± 93.8
210.6 ± 25.7
-10.5
0.4
PI/C
2.2 ± 1.1
2.0 ± 0.9
-0.2
0.3
IGI0-30
0.22 ± 0.4
0.21 ± 0.3
-0.1
0.9
IGI60-120
0.37 ± 0.6
0.35 ± 0.7
-0.2
0.8
HIE (%)
19.9 ± 4.1
20.3 ± 5.6
+0.4
0.7
C-ISI
3.3 ± 1.8
3.4 ± 1.3
+0.1
0.8
DI0-30 x C-ISI
0.73 ± 0.17
0.71 ± 0.15
-0.01
0.7
DI60-120 x C-ISI
1.16 ± 0.24
1.19 ± 0.27
+0.03
0.6
PI=Proinsulin, AUC=Area under the curve, IGI=Insulinogenic Index, HIE=Hepatic
Insulin Extraction, DI=Disposition Index Data presented as Mean ± SD
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Figures

	
  
Figure 5.1: Metabolic glucose clearance rate (MCR)
Skeletal glucose clearance rate based on five sample oral glucose tolerance test from the equation
established by Stumvoll et al. Data presented as Mean ± SD (*) p<0.05
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Figure 5.2: Subjective fatigue and quality of life
Subjective fatigue (Piper Fatigue Scale) and quality of life (EORTC QLQ-C30) determined by
subscale analysis. (A)- Fatigue severity subscale, (B) Subjective assessment of fatigue on
cognition/mood, (C) Fatigue Duration and (D) overall health and quality of life. Data presented as
mean ± SD. (*) p<0.05
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CHAPTER VI
SUMMARY AND CONCLUSIONS
The incidence and prevalence of both cancer and type 2 diabetes (T2D) are
increasing at alarming rates in the United States as well as other developed countries.
Physical activity decreases the risk of developing both diabetes and cancer (Kahn et al.
1993, Moore et al. 2016) and improves prognosis for those individuals who have already
received a diagnosis (Ballard-Barbash et al. 2012), however the exact mechanisms are
still unclear. While the changes to insulin supply (i.e. insulin secretion) and demand (i.e.
sensitivity) following lifestyle interventions or pharmacology in adults at risk for diabetes
and cancer have been investigated independently, relatively little is understood regarding
the effects of combined exercise training and pharmacology interventions. A recent
study from our lab suggested that adding metformin (a common anti-diabetes medication)
to exercise training did not enhance, and may have even blunted, the improvements to
insulin sensitivity derived from exercise training alone (Malin et al. 2012). While insulin
sensitivity and secretion represent key contributors to glycemic control, several other
factors that lie outside this systemic closed loop may play a role in the regulation of
diabetes risk. These tissue-specific responses may be more responsive to medication than
to exercise, and while the systemic response to exercise training and metformin may be
non-additive, that may not be the case within specific tissues. The purpose of study one
was therefore to investigate the independent and combined effects of exercise training
and metformin on aspects of insulin supply and demand that exist outside the typical
insulin supply and demand relationship.
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While this study was underway the consortium for the Transdisciplinary Research
into the Energetics of Cancer (TREC) began a study that also investigated the effects of
exercise training and/or metformin (Patterson et al. 2011). However instead of adults at
risk for diabetes, this project was evaluating the impact of exercise training and/or
metformin on cancer risk in a group of breast cancer survivors, in a four-arm approach
similar to study one. While this study will likely contribute significantly towards the
understanding of combined interventions on cancer recurrence, it may be limited by the
use of fasting insulin as the primary measure of insulin supply and demand. Given that
postmeal insulin exposure can be 50-80% of daily insulin exposure (Reaven, 1979) and
exercise training primarily reduces postmeal (not fasting) insulin concentrations in nondiabetic adults (Jenkins & Hagberg, 2011), evaluating an exercise training intervention
on the responses of fasting insulin alone may significantly underestimate the role of
exercise-induced reductions in insulin. The purpose of study two was to evaluate the
effects of exercise training on postmeal insulin concentrations in breast cancer survivors,
and determine if there was any relationship between the changes in postmeal insulin
concentrations and cancer-relevant biomarkers.
Finally, several aspects of breast cancer treatment may influence the mechanisms
behind fasting and postmeal insulin concentrations, such as insulin sensitivity, secretion
and beta cell function. As the number and longevity of breast cancer survivors increases,
more and more postmenopausal breast cancer survivors are at risk for cardiometabolic
disease. While significant contributions have been made to the understanding of exercise
induced cardioprevention and recovery of cardiovascular function in cancer survivors
following treatment, much less is understood regarding the recovery of metabolic
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function, such as insulin supply and demand. The purpose of study three was therefore to
evaluate the systemic and tissue-specific aspects of insulin supply and demand in breast
cancer survivors, and evaluate their response to exercise training.
Summary of study 1
Study 1 used a combination of a fasting blood draw and hyperinsulinemiceuglycemic clamp to evaluate several metrics of insulin supply and demand that lie
outside the closed loop of insulin secretion and sensitivity prior to and following an
exercise training and/or metformin intervention in adults with prediabetes. The three
specific outcomes were proinsulin processing, hepatic first pass insulin extraction, and
insulin clearance. Proinsulin concentrations are a reflection of how hard the beta cells of
the pancreas are working to produce insulin. We found that circulating proinsulin
concentrations were significantly reduced following combined exercise training and
metformin intervention, but were not different in exercise alone or placebo. Metformin
alone led to a decrease in proinsulin of approximately the same magnitude, however this
did not reach significance. We found no influence of any treatment on hepatic insulin
extraction, however there was a significant increase in the rate of insulin clearance during
the hyperinsulinemic euglycemic clamp in both metformin groups (metformin alone and
exercise plus metformin).
Taken together, these results suggest that while exercise training may have wideranging systemic effects on insulin supply and demand, metformin may work in a tissuespecific manner to regulate glycemic control. This result has significant implications for
researchers designing comparative efficacy studies as well as implications for clinicians
attempting to personalize lifestyle and pharmacological interventions to adults at risk for
118	
  
	
  

diabetes development. For example, it is possible that individuals with poor insulin
production and/or clearance but normal insulin sensitivity would derive more benefit
from metformin than they would from exercise training, whereas those adults with insulin
resistance would not only respond more favorably to exercise training than metformin,
but should possibly avoid the attenuating effects of metformin on exercise adaptations
should they begin an exercise training program while on metformin.
Summary of studies 2 and 3
Studies 2 and 3 investigated the impact of 12- weeks of personalized aerobic
exercise training on postmeal insulin concentrations (Study 2) and metrics of insulin
supply and demand (study 3) in postmenopausal breast cancer survivors. These two
studies were designed to be viewed in conjunction with each other, with study two
focused on the role of exercise-induced changes to insulin concentrations and their
relationship with cancer risk and recurrence, while study 3 was focused on the
cardiometabolic health of postmenopausal breast cancer survivors and the mechanisms by
which cancer treatment may influence diabetes risk through the mechanisms that regulate
insulin supply and demand. Participants significantly increased their physical activity
levels as a result of the exercise training intervention, attending an average of 34 sessions
over the 12 week period and engaging in 156 minutes/wk of supervised exercise. The
progressive nature of the exercise program was adhered to by the majority of the
participants, and both volume and intensity of exercise increased over the 12 week period
as participants fitness improved. Aerobic fitness significantly increased and weight
significantly decreased as a result of the exercise training program, suggesting that the
dose of exercise was sufficient to induce beneficial physiological adaptations.
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Additionally, participants had reduced levels of fatigue and improved quality of life. The
exercise training program could therefore be considered successful for the participants
based on those metrics alone, as quality of life and aerobic fitness represent areas where
cancer treatment has large detrimental effects.
While the exercise training intervention led to significant reductions in several
cancer biomarkers (e.g. leptin, 17b-estradiol) and a reduction in insulin concentrations 2
hours following the administration of an oral glucose challenge, exercise training did not
lower overall postmeal insulin concentrations or metrics of insulin supply and demand.
This result was surprising as a reduction in postmeal insulin concentrations and increase
in insulin sensitivity is often observed in exercise training interventions. A secondary
analysis of contributing factors to this lack of effect of exercise training suggests that
there was a significantly opposing effect of past/present aromatase inhibitor use on
metabolic adaptations to exercise training. Given the primary role of aromatase inhibitors
to reduce circulating estrogen concentrations in postmenopausal women, it is likely that
estrogen plays a role in the metabolic adaptations to exercise training in breast cancer
survivors. We observed a significant negative association between the change in peak
estrogen concentrations and change in peak insulin concentrations following exercise
training in women with past/present AI use, but not in those women who were not taking
or who had never taken AIs. Additionally, the change in insulin sensitivity (C-ISI) in
women who were not taking aromatase inhibitors was negatively correlated with percent
change in estrogen concentrations, but this was not the case for women taking AIs. While
this data presents a somewhat conflicting view of the role of estrogen in metabolic
adaptations to exercise training, it is clear that estrogen concentrations, and by proxy the
120	
  
	
  

use of estrogen lowering medications, may play a significant role in both cancer and
cardiometabolic disease risk in breast cancer survivors.
Conclusion
When taken together, these studies appear to shed some light on the nature of
exercise training as a means to modify two hormones that play opposing roles in the
pathophysiology of diabetes and cancer. While insulin and estrogen contribute to better
blood glucose control, the mitogenic properties inherent in both hormones likely make
them detrimental towards the prevention of cancer recurrence. Results from this
dissertation suggest that exercise training can reduce circulating concentrations of insulin,
however this is specific to the postmeal state. This response appears to be blunted in
individuals with a past or present history of aromatase inhibitor use. We also observed a
significant reduction in estrogen as a result of exercise, however the clinical implications
are unclear based on the relatively low levels at baseline. Exercise training may therefore
represent an option for managing post-treatment concentrations of hormones that have a
significant influence on cancer risk as well as diabetes development. This may go a long
way towards the idea of precision medicine, where the use of exercise, diet, and
pharmacolology (e.g. metformin) would be optimally integrated and combined with the
appropriate dose and duration of endocrine therapy in order to maximally reduce the risk
of cancer recurrence with minimal impact on diabetes risk. While this dissertation sheds
some light on the potential mechanisms behind the relationship between cancer
recurrence and diabetes risk following exercise training, it raises far more questions than
it answers. Future exercise training studies in postmenopausal breast cancer survivors that
focus on populations at high risk for diabetes, use gold-standard measures of insulin
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supply and demand and are designed to directly evaluate the role of estrogen and/or
aromatase inhibitor use are required before the dream of personalized precision posttreatment oncotherapy can become a reality.
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APPENDIX
INDIVIDUAL RESPONSES EXERCISE TRAINING IN BREAST CANCER
SURVIVORS
One of the strengths of studies 2 and 3 is the personal supervision of all exercise
training sessions. Because data was continuously collected throughout the exercise
training intevention on each participant, we are able to examine the progression of fitness
and evaluate whether these individual responses may have contributed to the overall
changes observed in fitness, body composition and cardiometabolic health. Presented
below are individual changes to exercise volume (Figure A1) and intensity (Figure A2)
broken into weeks 1-4, 5-8 and 9-12, along with the total number of sessions (Figure A3)
and the number of high intensity interval sessions (Figure A4).
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Figures

Figure A1: Exercise training volume
Individual changes to supervised exercise volume over the course of the 12 week
intervention period.

124	
  
	
  

Figure A2: Exercise training intensity
Individual changes to supervised exercise training intensity, reported as percent of agepredicted maximum heart rate (%HRmax) per session during the exercise training
intervention
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Figure A3: Exercise sessions
Total number of exercise sessions over the 12-week intervention period for each
participant enrolled in the study.
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Figure A4: High intensity interval sessions
Total number of high intensity interval training (HIIT) sessions by each participant over
the course of the 12-week intervention period
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